WO2016172054A1 - Systèmes et procédés pour empêcher le passage de dispositifs intragastriques - Google Patents

Systèmes et procédés pour empêcher le passage de dispositifs intragastriques Download PDF

Info

Publication number
WO2016172054A1
WO2016172054A1 PCT/US2016/028143 US2016028143W WO2016172054A1 WO 2016172054 A1 WO2016172054 A1 WO 2016172054A1 US 2016028143 W US2016028143 W US 2016028143W WO 2016172054 A1 WO2016172054 A1 WO 2016172054A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
volume
intragastric
inflation
gas
Prior art date
Application number
PCT/US2016/028143
Other languages
English (en)
Inventor
Mark Brister
Neil R. DRAKE
Antonio C. Llevares
Sheldon Nelson
Daniel J. PROCTOR
Andrew P. RASDAL
Keoni John SUNDSETH
Amy D.L. VANDENBERG
Betty Wong
Original Assignee
Obalon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obalon Therapeutics, Inc. filed Critical Obalon Therapeutics, Inc.
Publication of WO2016172054A1 publication Critical patent/WO2016172054A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F5/0036Intragastrical devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F5/003Implantable devices or invasive measures inflatable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F2005/0016Implantable devices or invasive measures comprising measuring means
    • A61F2005/002Implantable devices or invasive measures comprising measuring means for sensing mechanical parameters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0089Instruments for placement or removal

Definitions

  • Devices and methods for treating obesity are provided. More particularly, apparatuses and methods for preventing volume-occupying intragastric devices from passage through the digestion system, are provided.
  • Obesity is a major health problem in developed countries. Obesity puts you at greater risk of developing high blood pressure, diabetes and many other serious health problems. In the United States, the complications of being overweight or obese are estimated to affect nearly one in three American adults, with an annual medical cost of over $80 billion and, including indirect costs such as lost wages, a total annual economic cost of over $120 billion. Except for rare pathological conditions, weight gain is directly correlated to overeating.
  • Noninvasive methods for reducing weight include increasing metabolic activity to burn calories and/or reducing caloric intake, either by modifying behavior or with pharmacological intervention to reduce the desire to eat.
  • Other methods include surgery to reduce the stomach's volume, banding to limit the size of the stoma, and intragastric devices that reduce the desire to eat by occupying space in the stomach.
  • Intragastric volume-occupying devices provide the patient a feeling of satiety after having eaten only small amounts of food. Thus, the caloric intake is diminished while the person is satisfied with a feeling of fullness.
  • Currently available volume-occupying devices have many shortcomings. For example, complex gastric procedures are required to insert some devices.
  • U.S. Pat. No. 4,133,315 discloses an apparatus for reducing obesity comprising an inflatable, elastomeric bag and tube combination.
  • the bag can be inserted into the patient's stomach by swallowing. The end of the attached tube distal to the bag remains in the patient's mouth. A second tube is snaked through the nasal cavity and into the patient's mouth. The tube ends located in the patient's mouth are connected to form a continuous tube for fluid communication through the patient's nose to the bag.
  • the bag can be implanted by a gastric procedure. The bag is inflated through the tube to a desired degree before the patient eats so that the desire for food is reduced. After the patient has eaten, the bag is deflated. The tube extends out of the patient's nose or abdominal cavity throughout the course of treatment.
  • U.S. Pat. Nos. 4,416,267, 4,485,805, 4,607,618, 4,694,827, 4,723,547, 4,739,758, and 4,899,747 and European Patent No. 246,999 relate to intragastric, volume-occupying devices for weight control that can be inserted endoscopically.
  • U.S. Pat. Nos. 4,416,267, 4,694,827, 4,739,758 and 4,899,747 the contents of which are incorporated herein by reference in their entirety relate to balloons whose surface is contoured in a certain way to achieve a desired end.
  • the balloon is torus-shaped with a flared central opening to facilitate passage of solids and liquids through the stomach cavity.
  • the balloon of U.S. Pat. No. 4,694,827, the contents of which are incorporated herein by reference in their entirety, has a plurality of smooth- surfaced convex protrusions.
  • the protrusions reduce the amount of surface area which contacts the stomach wall, thereby reducing the deleterious effects resulting from excessive contact with the gastric mucosa.
  • the protrusions also define channels between the balloon and stomach wall through which solids and liquids may pass.
  • the balloon of U.S. Pat. No. 4,739,758, the contents of which are incorporated herein by reference in their entirety, has blisters on its periphery that prevent it from seating tightly against the cardia or pylorus.
  • the balloon is inserted into a finger cot that is attached by string to the end of a conventional gastric tube that is inserted down the patient's throat.
  • the balloon of European Patent No. 246,999 is inserted using a gastroscope with integral forceps.
  • the appliance is not inflatable. It is endoscopically inserted into the stomach using an especially adapted bougie having an ejector rod to release the collapsed appliance. Once released, the appliance returns to its greater relaxed size and shape.
  • U.S. Pat. No. 5,129,915 the contents of which are incorporated herein by reference in their entirety, relates to an intragastric balloon that is intended to be swallowed and that inflates automatically under the effect of temperature.
  • An intragastric balloon might be inflated by a change in temperature are discussed.
  • a composition comprising a solid acid and non-toxic carbonate or bicarbonate is separated from water by a coating of chocolate, cocoa paste or cocoa butter that melts at body temperature.
  • citric acid and an alkaline bicarbonate coated with non-toxic vegetable or animal fat melting at body temperature and which placed in the presence of water, can produce the same result.
  • the solid acid and non-toxic carbonate or bicarbonate are isolated from water by an isolation pouch of low-strength synthetic material which it will suffice to break immediately before swallowing the bladder. Breaking the isolation pouches causes the acid, carbonate or bicarbonate and water to mix and the balloon to begin to expand immediately.
  • a drawback of thermal triggering of inflation is that it does not afford the degree of control and reproducibility of the timing of inflation that is desirable and necessary in a safe self-inflating intragastric balloon.
  • Non-invasive methods for reducing weight can fail, causing serious implication for the patient.
  • intragastric volume-occupying devices deteriorate, allowing the body to absorb toxic material, or enter into digestion and cause blockage requiring exploratory surgery. Accordingly, apparatuses and methods to keep an intragastric volume- occupying device from becoming a catastrophic event for the patient are desirable.
  • a free-floating or tethered intragastric volume- occupying device or devices that maintain volume and/or internal pressure within a predetermined range over time, or which undergoes a predetermined adjustment in volume and/or internal pressure over time is disclosed.
  • the devices can be self-inflating (also referred to as automatic inflating) or inflatable (also referred to as manually inflating via a tether), and can include a mechanism to alert a leakage or deflation event.
  • volume-occupying devices and methods for manufacturing, deploying, inflating, tracking, locating, deflating and retrieving of such devices are provided.
  • the devices and methods of the preferred embodiments may be employed for treating over weight and obese individuals. Methods employing the device of the preferred embodiments need not utilize invasive procedures, but rather the device may simply be swallowed by a patient, with or without a catheter attached. Once in the stomach of the patient, the device is inflated with a preselected fluid, e.g., a gas, liquid, vapor or mixtures thereof, to a preselected volume.
  • a preselected fluid e.g., a gas, liquid, vapor or mixtures thereof
  • a "fluid,” such as an initial fill fluid also includes a material or materials in the solid, liquid, vapor, or gas phase that are incorporated within, mixed within, carried within or otherwise entrained in a fluid such as a gas or liquid.
  • a fluid can comprise one substance, or mixtures of different substances, and may be or include saline, physiologically acceptable fluids or substances, etc. as further described herein.
  • the wall of the device is preselected for its particular fluid, e.g. gas, diffusion properties.
  • the gas(es) within the device diffuse out through the wall of the device, and gases diffuse into the device from the in vivo environment.
  • the volume and/or internal pressure of the device can be maintained within a preselected range, or can follow a preselected profile of volume and/or pressure changes.
  • the device can be removed using endoscopic tools or will decrease in volume or deflate so as to pass through the remainder of the patient's digestive tract.
  • Inflation may be achieved by use of a removable catheter that initially remains in fluid contact with the device after it has been swallowed by the patient.
  • inflation may be achieved by a self-inflation process, e.g., generation of gas in the device once it reaches the stomach by reaction of gas-generating components contained within the device upon swallowing, or by introduction of one or more components in the gas generating process into the device by use of a removable catheter.
  • the volume-occupying subcomponent of devices may be formed by injection, blow or rotational molding of a flexible, gas-impermeable, biocompatible material, such as, for example, polyurethane, nylon or polyethylene terephthalate.
  • the volume-occupying subcomponent may be further coated with one or more gas-barrier compounds, or be formed of a Mylar polyester film coating or kelvalite, silver or aluminum as a metalized surface to provide a gas impermeable barrier.
  • the device employs a delivery state in which the device is packaged such that the device may be swallowed while producing minimal discomfort to the patient.
  • the device may be packaged into a capsule.
  • the device may be coated with a material operable to confine the device and facilitate swallowing.
  • Various techniques may also be employed to ease swallowing of the device including, for example, wetting, temperature treating, lubricating, and treating with pharmaceuticals such as anesthetics.
  • the devices incorporate a component or components that prevent the intragastric balloon from passage out of the stomach, both in an inflated state and in a state of complete or partial failure (deflation or leakage).
  • the component can be incorporated into the balloon or a component thereof or therein, or can be provided as an additional component added to or affixed to the balloon or a component thereof or therein.
  • FIG. 1 illustrates an example embodiment of an umbrella structure for maintaining the size of an intragastric volume occupying device.
  • FIG. 2 illustrates an example embodiment of an intragastric volume occupying device equipped with hemispherical rings for maintaining the size of the device.
  • FIG. 3 illustrates an example embodiment of hydraulic scaffolding internal to the intragastric volume occupying device.
  • FIGS. 4A-D illustrate a foldable ring internal to the intragastric device.
  • FIG. 5 illustrates an example embodiment of the intragastric volume occupying device equipped with a CardioMEMS for monitoring the pressure of the balloon.
  • FIGS. 6A-D illustrate example embodiments of an intragastric volume occupying device equipped with a secondary balloon within the device for maintaining the size of the device.
  • FIGS. 7A and 7B-C illustrate example embodiments of an intragastric volume occupying device containing a hydrogel material for maintaining the size of the device.
  • the device of FIG. 7A contains a spherical hydrogel material and the device of FIGS 7B-C contains a toroidal hydrogel.
  • FIG. 8 illustrates an example embodiment of an intragastric volume occupying device equipped with magnets whose orientation of magnetic poles creates repulsion to maintain the size of the device.
  • the term "degradable” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a process by which structural integrity of the balloon is compromised (e.g., by chemical, mechanical, or other means (e.g., light, radiation, heat, etc.) such that deflation occurs.
  • the degradation process can include erosion, dissolution, separation, digestion, disintegration, delamination, comminution, and other such processes. Degradation after a predetermined time, or within a predetermined window of time, after ingestion is particularly preferred.
  • C0 2 barrier material as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a material having a permeability to C0 2 of 10 cc/m /day or less under simulated in vivo conditions (100% humidity and body temperature of 37°C).
  • in vivo conditions refers to both actual in vivo conditions, such as in vivo intragastric conditions, and simulated in vivo conditions. The permeability of a material to C0 2 may vary depending upon the conditions under which it is measured.
  • swallowable is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to ingestion of a balloon by a patient such that the outer capsule and its constituents are delivered to the stomach via normal peristalsis movement. While the systems of preferred embodiments are swallowable, they are also configured by ingestion by methods other than swallowing. The swallowability of the system is derived, at least in part, by the outer container size for the self-inflating system and the catheter and outer container size for the manual inflation system.
  • the outer capsule is sufficient to contain the inner container and its constituents, an amount of activation agent injected prior to administration, the balloon size, and the balloon material thickness.
  • the system is preferably of a size less than the average normal esophagus diameter.
  • Described herein is a system for an orally ingestible device with one or more failure indicating components.
  • the device is able to traverse the alimentary canal.
  • the device may be useful, for example, as an intragastric volume-occupying device.
  • the device overcomes one or more of the above- described problems and shortcomings found in current intragastric volume- occupying devices. While in certain embodiments specific devices are described, it is understood that the materials and methods can also be applied to other devices.
  • a swallowable, self-inflating or inflatable intragastric balloon system includes the following components: self-sealing valve system for addition of fluid to the lumen of the balloon or to the inner container (“valve system”), a balloon in a deflated and compacted state (“balloon”) and an outer capsule, container, or coating (“outer container”) that contains the balloon.
  • valve system for addition of fluid to the lumen of the balloon or to the inner container
  • outer container an outer capsule, container, or coating
  • an inner capsule or other container that contains one or more C0 2 generating components is present inside the lumen of the balloon.
  • the system may also include various components for facilitating delivery (“delivery components") of the balloon to the mouth and/or through the esophagus.
  • an inflation fluid source, a catheter, and tubing are provided for inflating the balloon after ingestion or placement in the stomach.
  • the valve is preferably attached to the inner surface of the balloon by an adhesive or other means (e.g., welding), and provided with an inoculation spacer to prevent puncture of the wall of the balloon and inner container by a needle or other means for injecting an liquid activation agent into the lumen of the balloon via the self- sealing valve.
  • a valve providing releasable attachment of the tubing to the balloon is provided in the inflatable balloon configuration.
  • the self-sealing valve system attached to the balloon (e.g., on its inside surface) in the inflatable configuration is "universal" or compatible with a swallowable catheter or a physician-assisted catheter.
  • the valve system serves to allow for balloon inflation using a miniature catheter that includes a needle assembly and also provides a mechanism for detachment of the catheter after inflation has been completed.
  • the outer container preferably incorporates the balloon in a compacted state (e.g., folded and rolled), preferably with sufficient space to allow for activation liquid to be injected into the balloon in the self-inflating balloon configuration, wherein the liquid activation agent initiates separation, erosion, degradation, and/or dissolution of the inner container and generation of C0 2 upon contact with the inflation agent contained within the inner container, which subsequently causes outer container separation, erosion, degradation, and/or dissolution due to C0 2 gas pressure.
  • the outer container need only incorporate the balloon in a compacted state.
  • Selected components of a swallowable intragastric balloon system of a preferred embodiment can include a silicone head with radioopacity ring, trimmed 30 D silicone septum, Nylon 6 inoculation spacer, compacted balloon, inner container (if self-inflating), and outer container as constituents of the system in unassembled form.
  • a fully assembled outer container can include a vent hole aligned with a septum for puncture to inject liquid activation agent (if self-inflating) or a port for connection of tubing (if inflatable).
  • the components of particularly preferred systems possess the attributes described herein; however, in certain embodiments systems can be employed which utilize components having other attributes and/or values.
  • Devices according to the preferred embodiments are intended for ingestion by a patient and deployment without the need to resort to invasive methods. It is therefore desirable that the device of the preferred embodiments be operable to conform to a compact delivery state which can be swallowed by a patient with minimal discomfort. Once in the stomach, it is desirable for the device to assume a substantially larger deployed state. In order to achieve the transition from a delivery state to a deployed state the device is subjected to inflation.
  • the inflation subcomponent may require outside inputs such as an activation agent.
  • the activation agent is preferably injected using a syringe having a needle with a gauge diameter of from 25 to 32.
  • the needle length is preferably from about 0.25 inches (0.6 cm) to 1 inches (2.54 cm) in length so as to create a flow rate that allows for delivery of the full volume of inflation agent within 30 seconds, but in a manner/stream/flow that does not physically damage the inner container, thereby causing premature C0 2 generation and inflation.
  • the activation agent is preferably pure water, or a solution containing up to 50 % concentration of anhydrous citric acid at 20°C, or the equivalent thereof at varying solution temperatures based on solubility of anhydrous citric acid.
  • the system is configured to have an occupyable void space in the central lumen of the balloon when in compacted form in the outer container of from about 0.3 ml to about 4.5 ml, such that a corresponding volume of activation agent can be injected into the void space.
  • the free-floating inner container with inflation agent for C0 2 generation is preferably vertically aligned with the self-sealing valve system such that the septum/inoculation spacer is placed directly above the tip of the capsule.
  • the balloon contains an inner container.
  • a self-sealing valve system is adhesively adhered to the interior of the wall of the balloon, and the inverted configuration of the balloon is provided by inversion through a hole sealed with a patch.
  • the top approximate 1 ⁇ 4 of the balloon wall is folded over the inner capsule, and the pleats where the capsule is are creased similar to the pleats formed in the second step of making a paper airplane, then folded over to the left or to the right.
  • the bottom approximate 3 ⁇ 4 of the sphere is then accordioned using no more than 2 creases and folded over the capsule.
  • the left half is then folded over the right half of the capsule or vice versa so that the wings touch.
  • the material is rolled over until it creates a tight roll.
  • the device is then placed inside the outer container.
  • the balloon is folded so as to form a pocket around the inner capsule, to insure that the liquid injected through the self-sealing valve system is contained in an area less than 10% of the entire balloon surface area. It is not necessary to provide a pocket in the inflatable configuration, as no inner capsule is provided.
  • the balloon is folded such that the number of total folds is minimized so as to minimize possible damage to the outer material or compromise of barrier properties.
  • the number of total folds is preferably less than 10 folds.
  • the balloon material is rolled when at all possible such that the number of creases required to fit the balloon in an outer container is minimized. This is done in effort to also to prevent lumen material damage.
  • the self-sealing valve is also preferably constructed off-center of the balloon so as to minimize the number of folds that layer on top of each other.
  • the material forming the wall of the balloon is processed and folded to maximize reaction efficiency by localizing the initiation agent injected into the balloon so that it is maintained proximal to the reactants within the inner container.
  • the balloon is folded such that once the reaction initiates and the outer container separates, the balloon unfolds in a manner that creates the largest possible surface area, which prohibits the balloon from readily passing through the pyloric sphincter.
  • the ratio of reactants in the inflation agent and activation agent are selected such that the pH of any remnant liquid inside the lumen of the balloon is acidic, with a pH of less than 6, such that any balloon leakage or breach that allows stomach acid to enter does not cause additional C0 2 generation and resulting unintentional re-inflation.
  • an inflation agent is compressed, formed or otherwise held in a shape which provides good surface area availability for the reactants for C0 2 generation, while minimizing the space and/or volume sufficient to hold the inner container.
  • the inner container has a length (longest dimension) of from about 0.748 inches (1.9 cm) to 1.06 inches (2.7 cm) and a diameter or width of from about 0.239 inches (0.6 cm) to about 0.376 inches (1 cm).
  • the volume of the inner container is preferably from about 0.41 ml to about 1.37 ml.
  • the inner container is preferably in the form of a standard push-fit gelatin capsule but a gelatin tape may be used in lieu of a push-fit capsule.
  • the container is preferably relied upon for containing the inflation agent; however, additional sealing or other encapsulation can be employed to control timing of inflation.
  • Gelatin is particularly preferred for use as the inner container; however other materials can also be suitable for use, e.g., cellulose.
  • Timing is also controlled by compacting the balloon such that the activation agent is substantially localized in the balloon next to the inner capsule, creating an efficient C0 2 self-inflation method.
  • Balloon inflation is initiated by the liquid activation agent causing degradation of the inner container, such that the inflation agent in the inner container contacts the liquid activation agent, thereby initiating the gas generation reaction.
  • the inner container for the self-inflating balloon is contained within the lumen of the balloon and contains the C0 2 generator for balloon self-inflation.
  • the C0 2 generator comprises an inflation agent mixture housed within the container.
  • the total inflation agent used comprises powdered citric acid, with the remainder comprising powdered sodium bicarbonate.
  • Sufficient inflation agent is provided such that upon completion of the C0 2 generating reaction, the balloon achieves inflation at the nominal inflation pressure described above.
  • a total of from about 0.28 to 4 grams inflation agent mixture is employed, depending upon the balloon size to be inflated; preferably up to 1.15 grams of sodium bicarbonate is used with the remainder being powdered citric acid to generate 300 cm 3 of C0 2 at nominal pressure.
  • the balloon is preferably provided in a deflated and folded state in a capsule or other retaining, containing or coating structure ("outer container").
  • the outer container is preferably in the form of a standard push-fit gelatin capsule, with the push-fit relied upon for containing the deflated/folded balloon; however, a gelatin wrap can advantageously be employed in certain embodiments.
  • Gelatin is particularly preferred for use as the outer container; however other materials can also be suitable for use, e.g., cellulose, collagen, and the like.
  • the outer container has a length (longest dimension) of from about 0.95 inches (2.4 cm) to 2.5 inches (6.3 cm) and a diameter or width of from about 0.35 inches (0.9 cm) to about 0.9 inches (2.4 cm).
  • the volume of the inner container is preferably from about 1.2 ml to about 8.25 ml.
  • the outer container is preferably configured with one or more holes, slits, passageways or other egresses, preferably on each end, which act as vents such that any gas created due to inflation agent exposure to condensation or other ambient moisture present during processing does not cause premature separation or degradation of the inner container prior to 30 seconds after inoculation of the liquid activation agent, which may have an undesirable effect on reaction efficiency.
  • Such egresses can also expedite dissolution of the outer container to prepare the balloon for inflation in the inflatable configuration.
  • the process of the outer capsule degrading e.g., separates, dissolves, or otherwise opens
  • pressure build up caused by inflation (self-inflation or inflation via catheter) of the balloon.
  • the outer capsule can be dipped in water for a brief time to soften the materials but not release the balloon prior to swallowing to minimize the time lapse between swallowing and balloon inflation.
  • the outer container is provided with a hole to house the inflation tube needle assembly, wherein the diameter of the catheter needle housing is mechanically compatible with the diameter of the outer container hole such that the needle can be inserted into the self- sealing valve while maintaining therein the housed balloon to facilitate pushing or swallowing of the balloon assembly.
  • the outer container is a capsule.
  • the distal half of the capsule may be flared to prevent abrasion of the balloon materials by the leading edge of the capsule as the compacted balloon is inserted into the capsule.
  • the capsule can also comprise two parts held together with a gel band and encompassing the folded balloon that allows for quicker separation of the capsule so that inflation can take place more expeditiously.
  • the outer capsule degrades (e.g., separates, dissolves, or otherwise opens) due to contact with ingested fluid ingestion (e.g., water intake) and preferably degrades within 5 minutes or less, more preferably within 2 minutes or less, so as not to cause discomfort to the patient while the balloon/catheter tube is in place.
  • ingested fluid ingestion e.g., water intake
  • the device is fitted into a standard sized gelatin capsule.
  • the capsule may be formed of a material that has a known rate of degradation such that the device will not be released from the capsule or otherwise deployed prior to entry into the stomach.
  • the capsule materials may include one or more polysaccharide and/or one or more polyhydric alcohols.
  • the device in its delivery state, may be coated in a substance that confines the device in its delivery state while also facilitating swallowing.
  • the coating may be applied by a dipping, sputtering, vapor deposition, or spraying process which may be conducted at an ambient or positive pressure.
  • the encapsulated or coated device is lubricated or otherwise treated so as to facilitate swallowing.
  • the encapsulated or coated device may be wetted, heated, or cooled, prior to swallowing by the patient.
  • the encapsulated or coated device may be dipped in a viscous substance that will serve to lubricate the device's passage through the esophagus.
  • examples of possible coatings can be any substances with lubricious and/or hydrophilic properties and include glycerine, polyvinylpyrrolidone (PVP), petroleum jelly, aloe vera, silicon-based materials (e.g. Dow 360) and tetrafluoroethylene (TFE).
  • the coating may also be applied by a sputtering, vapor deposition or spraying process.
  • the coating or capsule is impregnated or treated with one or more local anesthetics or analgesics to ease swallowing.
  • anesthetics may include anesthetics in the amino amide group, such as articaine, lidocaine and trimecaine, and anesthetics in the amino ester group, such as benzocaine, procaine and tetracaine.
  • analgesics may include chloraseptic.
  • the capsule may be weighted at a certain end in order for it to be oriented appropriately when it is administered, as it travels down the esophagus, and/or when it is in the stomach.
  • the weighting components may include polymer materials or inflation reactants.
  • the swallowable, self-inflating intragastric balloon is provided with mechanisms to reliably control timing of self-inflation such that premature inflation while in the esophagus during swallowing is avoided and sufficient inflation once in the stomach so as to prevent passage through the pyloric sphincter is ensured.
  • Normal esophageal transit time for large food particles has been documented as 4-8 seconds, and gastric emptying of large food particles through the pylorus does not occur for at least 15-20 minutes.
  • the outer container is preferably configured to separate, dissolve, degrade, erode, and/or otherwise allow the deflated/folded balloon to begin unfolding not less than 60 seconds but not more than 15 minutes after inoculation with liquid activation agent.
  • the inner container is preferably configured chemically, mechanically or a combination thereof to retard the initial C0 2 generating chemical reaction such that sufficient C0 2 to begin inflating the balloon is not available earlier than 30 seconds after inoculation with the liquid activation agent, but to permit generation of sufficient C0 2 such that at least 10% of the occupyable volume of the balloon is filled within 30 minutes, at least 60% of the occupyable volume of the balloon is filled within 12 hours, and at least 90% of the occupyable volume of the balloon is filled within 24 hours.
  • This timing allows for injection of the activation agent into the outer container by the medical professional, passing the device to the patient, and swallowing by normal peristaltic means by the patient. This timing also prohibits potential passing of an uninflated balloon into the duodenum by the balloon being inflated to a sufficient size such that gastric emptying of the balloon cannot be easy, as objects more than 7 mm in diameter do not readily pass.
  • an administrator of the device may use a delivery tool for delivering the device to the mouth or facilitating its passage through the esophagus in the optimal orientation.
  • a delivery tool may enable the device administrator to inject the device with one or more inflation agents or inflation gases as part of administering the device to the patient.
  • such injection may be accomplished in the same mechanical action(s) of the administrator that are employed to release the device from the delivery tool into the mouth or esophagus.
  • the delivery tool may include a plunger, a reservoir containing a fluid, and an injection needle. The administrator pushes the plunger which, either in sequence or approximately simultaneously, forces the injection needle into the device and thereby injects the liquid contained in reservoir into the device.
  • the delivery tool may also include a subcomponent that administers an anesthetic or lubricant into the patient's mouth or esophagus to ease the swallowability of the device.
  • the volume-occupying subcomponent (“balloon") of the preferred embodiments is generally formed of a flexible material forming a wall which defines an exterior surface and an interior cavity.
  • Various of the above- described subcomponents may be either incorporated into the wall or interior cavity of the volume- occupying subcomponent.
  • the volume-occupying subcomponent can vary in size and shape according to the patient's internal dimensions and the desired outcome.
  • the volume-occupying subcomponent may be engineered to be semi-compliant, allowing the volume-occupying subcomponent to stretch or expand with increases in pressure and/or temperature. Alternatively, in some embodiments, a compliant wall offering little resistance to increases in volume may be desirable.
  • volume-occupying subcomponents are preferred in certain embodiments.
  • the volume-occupying subcomponent may be constructed to be donut-shaped, with a hole in the middle of it, and may be weighted and shaped in such a way that it orients in the stomach to cover all or part of the pyloric sphincter, similar to a check valve.
  • the hole in the middle of the volume- occupying subcomponent can then serve as the primary passage for the contents of the stomach to enter the small intestine, limiting the passage of food out of the stomach and inducing satiety by reducing gastric emptying.
  • Volume-occupying subcomponents may be manufactured with different-sized donut-holes according to the degree that gastric emptying is desired to be reduced. Delivery, inflation and deflation of the volume- occupying subcomponent may be accomplished by any of the methods described above.
  • volume-occupying subcomponent wall it is advantageous for the volume-occupying subcomponent wall to be both high in strength and thin, so as to minimize the compacted volume of the device as it travels the esophagus of the patient.
  • the volume-occupying subcomponent wall materials are manufactured with a biaxial orientation that imparts a high modulus value to the volume-occupying subcomponent.
  • the volume-occupying subcomponent is constructed of a polymeric substance such as polyurethane, polyethylene terephthalate, polyethylene naphthalate, polyvinyl chloride (PVC), Nylon 6, Nylon 12, or poly ether block amide (PEBA).
  • the volume- occupying subcomponent may be coated with one or more layers of substances that modify (increase, reduce, or change over time) gas-barrier characteristics, such as a thermoplastic substance.
  • the gas-barrier materials have a low permeability to carbon dioxide or other fluids that may be used to inflate the volume-occupying subcomponent.
  • the barrier layers should have good adherence to the base material.
  • Preferred barrier coating materials include biocompatible poly(hydroxyamino ethers), polyethylene naphthalate, polyvinylidene chloride (PVDC), saran, ethylene vinyl alcohol copolymers, polyvinyl acetate, silicon oxide (SiOx), acrylonitrile copolymers or copolymers of terephthalic acid and isophthalic acid with ethylene glycol and at least one diol.
  • Alternative gas-barrier materials may include polyamine-polyepoxides.
  • gas-barrier materials which may be applied as coatings to the volume-occupying subcomponent include metals such as silver or aluminum.
  • Other materials that may be used to improve the gas impermeability of the volume-occupying subcomponent include, but are not limited to, gold or any noble metal, PET coated with saran, conformal coatings and the like, as listed, for example, in Tables la-b.
  • the volume-occupying subcomponent is injection, blow or rotational molded. Either immediately following such molding, or after a period of curing, the gas-barrier coating may be applied if not already applied within the composite wall.
  • the intragastric volume-occupying subcomponent is formed using a Mylar polyester film coating silver, aluminum or kelvalite as a metalized surface, to improve the gas impermeability of the volume-occupying subcomponent.
  • the volume-occupying subcomponent's wall is composed of multiple layers of materials
  • Such substances can include a solvent or an ether- based adhesive.
  • Such multiple layers may also be heat-bonded together.
  • a volume-occupying subcomponent comprised of a combination of PET and SiOx layers, which impart favorable mechanical and gas impermeability characteristics to the volume- occupying subcomponent, may be sealed by including a layer of sealable polyethylene in such volume-occupying subcomponent.
  • the functionality of the volume-occupying subcomponent and the deflation component is combined either in part or in whole.
  • the volume-occupying subcomponent may be formed of a substance that is degraded within the stomach over a desired period of time. Once the degradation process has formed a breach in the wall of the volume- occupying subcomponent, the volume-occupying subcomponent deflates, continues to degrade and passes through the remainder of the digestive tract.
  • an automated process is employed that takes a fully constructed volume-occupying subcomponent, evacuates all of the air within the interior cavity and folds or compresses the volume-occupying subcomponent into the desired delivery state.
  • the evacuation of air from the volume-occupying subcomponent may be actuated by vacuum or mechanical pressure (e.g. rolling the volume-occupying subcomponent).
  • vacuum or mechanical pressure e.g. rolling the volume-occupying subcomponent.
  • Deflation and/or inflation of the volume-occupying subcomponent may be achieved through one or more injection sites within the wall of the volume-occupying subcomponent.
  • two self-sealing injection sites can be incorporated at opposite sides of the volume-occupying subcomponent.
  • the volume-occupying subcomponent may be positioned within a fixture that employs two small-gauge needles to evacuate the air from the volume-occupying subcomponent.
  • the self-sealing injection sites may further be used to insert chemical elements of the inflation subcomponent into the interior of the volume- occupying subcomponent. After injection of the chemical elements into the volume- occupying subcomponent, the same needles may be used to perform evacuation of the volume-occupying subcomponent.
  • volume-occupying subcomponent is packed into the delivery state under, for example, a negative vacuum pressure or under a positive external pressure.
  • volume- occupying subcomponent wall materials may also be engineered to, once they are initially punctured or torn, tear relatively easily from the point of such puncture or tear.
  • Such properties can, for example, be advantageous if deflation of the volume-occupying subcomponent were initiated by a tearing or puncturing of the volume-occupying subcomponent wall, since such initial tear or puncture may then increase in scope, hastening and/or maximizing the deflation process.
  • the volume-occupying subcomponent may also be coated by a lubricious substance that facilitates its passage out of the body following its deflation.
  • a lubricious substance that facilitates its passage out of the body following its deflation.
  • coatings can be any substances with lubricious and/or hydrophilic properties and include glycerine, polyvinylpyrrolidone (PVP), petroleum jelly, aloe vera, silicon-based materials (e.g. Dow 360) and tetrafluoroethylene (TFE).
  • PVP polyvinylpyrrolidone
  • TFE tetrafluoroethylene
  • the coating may be applied by a dipping, sputtering, vapor deposition or spraying process which may be conducted at an ambient or positive pressure.
  • the balloon composite wall materials can be of similar construction and composition as those described in U.S. Patent Publication No. 2010-0100116-Al, the contents of which is hereby incorporated by reference in its entirety.
  • the materials are able to contain a fluid, preferably in compressed or non-compressed gas form, such as, e.g., N 2 , Ar, 0 2 , C0 2 , or mixture(s) thereof, or atmospheric air (composed of a mixture of N 2 , 0 2 , Ar, C0 2 , Ne, CH 4 , He, Kr, H 2 , and Xe) that simulate gastric space concentrations.
  • the balloon is able to hold the fluid (gas) and maintain an acceptable volume for up to 6 months, preferably for at least 1 to 3 months after inflation.
  • Particularly preferred fill gases include non-polar, large molecule gases that can be compressed for delivery.
  • the balloon Prior to placement in the outer container, the balloon is deflated and folded. In the inverted configuration in a deflated state, the balloon is flat, with the inverted seam extending around the perimeter of the balloon.
  • the self-sealing valve system is affixed to the inner wall of the lumen close to the center of the deflated balloon, with the inner container positioned adjacent to the self-sealing valve system. The walls of the balloon are then folded.
  • the self-sealing valve system is manufactured in a manner such that it is placed "off center” to minimize the number of folds upon themselves (e.g., doubling or tripling up) required to fit the balloon in the outer container.
  • the self-sealing valve system can advantageously be placed 1 ⁇ 2 r ⁇ 1 ⁇ 4 r from the center of the balloon, wherein r is the radius of the balloon along a line extending from the center of the balloon through the septum.
  • a self-inflating balloon is fully sealed 360 degrees around.
  • the self-inflating configuration with injection of an inflation agent by needle syringe, there are preferably no external openings or orifices to the central lumen.
  • a valve structure (either protruding, recessed, or flush with the surface of the balloon) is provided for providing an inflation fluid to the central lumen.
  • the balloon can have a "noninverted,” “inverted,” or “overlapped” configuration. In a "noninverted” configuration, the seams or welds and seam allowance, if any, are on the outside of the inflated balloon.
  • an “overlapped” configuration layers are overlapped, optionally with one or more folds, and secured to each other via welds, a seam, adhesive, or the like, resulting in a smooth external surface.
  • the balloon In an "inverted” configuration, the balloon has a smooth external surface with seams, welds, adhesive bead, or the like inside the inflated balloon.
  • two balloon halves are joined together in some fashion (e.g., adhered using adhesive or heat or the like based on the balloon material used).
  • One of the balloon halves encompasses an opening to allow for the balloon to be pulled through itself after adherence of the two halves and to have the seams of the balloon on the inside.
  • the opening created is preferably circular but can be any similar shape, and the diameter of the opening preferably does not exceed 3.8 cm; however, in certain embodiments a larger diameter may be acceptable.
  • a patch of material is adhered (adhesively, heat welded, or the like, based on the material used) to cover the original balloon- half opening. The inversion hole thus created that is subsequently patched is small enough that the forces exerted during inflation do not compromise the material used to maintain fluid in the balloon.
  • the preferred shape for the inflated balloon in final assembly is ellipsoid, preferably spheroid or oblate spheroid, with nominal radii of from 1 inch (2.5 cm) to 3 inches (7.6 cm), a nominal height of from 0.25 inches (0.6 cm) to 3 inches (7.6 cm), a volume of from 90 cm 3 to 350 cm 3 (at 37°C and at internal nominal pressure and/or full inflation), an internal nominal pressure (at 37°C) of 0 psi (0 Pa) to 15 psi (103421 Pa), and a weight of less than 15 g.
  • the self-inflating balloon is configured for self-inflation with C0 2 and is configured to retain more than 75% of the original nominal volume for at least 25 days, preferably for at least 90 days when residing in the stomach.
  • the inflatable balloon is configured for inflation with an appropriate mixture of gases so as to deliver a preselected volume profile over a preselected time period (including one or more of volume increase periods, volume decrease periods, or steady state volume periods).
  • the balloon is configured to maintain a volume of at least 90% to 110% of its original nominal volume.
  • the balloon can be desirable for the balloon to increase and/or decrease in volume over its useful life (e.g., in a linear fashion, in a stepwise fashion, or in another non-linear fashion). In other embodiments, the balloon maintains a volume of 75% to 125% of its original nominal volume, or 75% to 150%.
  • the intragastric device can be a single free-floating or tethered device. In some embodiments, it can be desirable to provide multiple devices (2, 3, 4, 5, 6, or more), either free-floating or tethered to each other, e.g., in a similar configuration to a cluster of grapes.
  • the individual devices can be simultaneously inflated with one inflation system connected to all of the devices, or each device can be provided with a separate inflation system.
  • a self-sealing valve system which contains a self- sealing septum housed within a metallic concentric cylinder.
  • the self-sealing valve system is preferably adhered to the underside of the balloon material such that only a portion of the valve protrudes slightly outside of the balloon surface to ensure a smooth surface.
  • the valve system for the inflatable configuration can utilize the same self-sealing septum designed for the self-inflating configuration.
  • the septum preferably consists of a material possessing a durometer of 20 Shore A to 60 Shore D. The septum is inserted or otherwise fabricated into the smaller cylinder of the concentric metallic retaining structure that is preferably cylindrical in shape.
  • the smaller cylinder within the larger cylinder controls alignment of the catheter needle sleeve/needle assembly with the septum, provides a hard barrier so that the catheter needle does not pierce the balloon material (needle stop mechanism), and provides compression such that the valve/septum re-seals after inflation and subsequent needle withdrawal.
  • the concentric valve system can also provide radio opacity during implantation and is preferably titanium, gold, stainless steel, MP35N (nonmagnetic, nickel- cobalt-chromium-molybdenum alloy) or the like.
  • Non-metallic polymeric materials can also be used, e.g., an acrylic, epoxy, polycarbonate, nylon, polyethylene, PEEK, ABS, or PVC or any thermoplastic elastomer or thermoplastic polyurethane that is fabricated to be visible under x-ray (e.g., embedded with barium).
  • the septum is preferably cone shaped, so that the compressive forces are maximized for self-sealing after inflation.
  • the self-sealing septum allows air to be evacuated from the balloon for processing/compacting and insertion into the outer container, and allows for piercing by an inflation agent syringe needle (self-inflating configuration) or inflation catheter needle (inflatable configuration), and then subsequent withdrawal of the inflation agent syringe needle or detachment of the inflation catheter and withdrawal of the catheter needle significantly limiting gas leakage outside of the balloon during the inflation process and needle withdrawal/catheter detachment.
  • the septum is inserted into the valve using a mechanical fit mechanism to provide compression.
  • An additional ring can be placed at the distal end of the inner cylinder to provide additional compression to ensure the septum material is dense enough to re-seal itself.
  • the ring is preferably metallic in nature, but can also be a non-metallic polymeric material such as an acrylic, epoxy, or thermoplastic elastomer or thermoplastic polyurethane.
  • the ring material is preferably the same material as the cylinder, titanium, but can also be gold, stainless steel, MP35N or the like.
  • a larger, outer cylinder of the concentric valve housing contains a slightly harder durometer material than the inner cylinder (50 Shore A or greater), but is also preferably silicone.
  • the purpose of using a harder durometer material is to ensure sealing when connected to the needle sleeve for inflation.
  • the silicone located in the outer ring of the concentric valve is adhered to the balloon from the inside surface.
  • the entire outer cylinder is filled and a small circular lip of this same material is provided that is slightly larger than the diameter of the inner cylinder and extends to the outside surface of the balloon. The lip is compatible with the bell shaped needle sleeve and provides sealing to enhance connection of the valve to the catheter to withstand the inflation pressures applied and also increases the tensile force of the catheter.
  • This silicone lip preferably does not protrude past the balloon surface more than 2 mm to ensure that the balloon surface remains relatively smooth and does not cause abrasion or ulcerations of the mucosa. It is designed to provide compressive forces against the needle sleeve of the catheter for inflation and detachment whereby when connected to the needle sleeve of the inflation catheters, the connection force during the inflation process can withstand up to 35 PSI. The seal is then broken during detachment using hydrostatic pressure that is more than 40 PSI less than 200 PSI to break the connection force.
  • Two additional retaining rings are included in the valve system to further enhance the seal between the metal and the valve silicone and provide additional mechanical support to ensure proper mechanical fit and are intended to disrupt slippage of the silicone material from the hard (metallic) valve system (causing an increase in tensile force).
  • the valve structure for the inflatable configuration uses a mechanical fit mechanism to provide the functions of the self-sealable valve for inflation by the catheter and subsequent catheter detachment; however, primer and/or adhesive may be used to provide additional support in maintaining the assembly.
  • the configuration can be modified by modifying the surfaces of the metal components, making them more sticky or slippery to provide the desired mechanical/interference fit.
  • the interference fit between the valve and the catheter can be modified to change the pressure requirements for inflation and/or detachment.
  • Additional assemblies can include overmolding the metallic portions or the concentric system in silicone such that additional support rings to ensure the mechanical fit and the tensile strength and forces required to sustain the assembly during catheter inflation and detachment can be omitted.
  • the total valve diameter in the inflatable configuration is designed to fit a miniature catheter system that does not exceed 8 French (2.7 mm, 0.105 inches) in diameter.
  • the total diameter does not exceed 1 inch (2.54 cm) and is preferably less than 0.5 inches (1.27 cm), to facilitate swallowing.
  • Additional valves can be added, if desired; however, it is generally preferred to employ a single valve so as to maintain the volume of the deflated/folded balloon (and thus the outer container dimensions) as small as possible.
  • the valve system is preferably attached to the inner surface of the balloon such that a shear force greater than 9 lbs (40 N) is required to dislodge the valve system.
  • the valve system can be attached to the balloon (e.g., on its inside surface) without the use of an opening, orifice, or other conduit in the wall of the balloon.
  • the valve system can utilize a septum with a durometer of 20 Shore A to 60 Shore D.
  • the valve can be inserted or otherwise fabricated into a retaining structure that has a higher durometer, e.g., 40 Shore D to 70 Shore D or more.
  • the retaining structure can be fabricated from a silicone, rubber, soft plastic or any suitable non-metallic polymeric material such as an acrylic, an epoxy, a thermoplastic elastomer, or thermoplastic polyurethane.
  • a structure such as a ring, that can be metallic or non-metallic but radioopaque (e.g., barium) and visible under X-ray, or magnetic or magnetizable and detectable by sensing of a magnetic field, can be embedded in the retaining structure.
  • radioopaque e.g., barium
  • a structure such as a ring
  • one softer (septum) with a large diameter can be inserted into a snug, more rigid durometer structure creates compressive forces in the once open orifice to enable C0 2 retention and reduce susceptibility for C0 2 gas leaks.
  • the metallic ring for radio- opacity also helps to create compressive forces on the septum.
  • the self-sealing septum allows air to be evacuated from the balloon for processing/compacting and inserting in the outer container, and also allows for the inflation agent to be injected into the outer container for inflation initiation. Additional septums can be provided, if desired; however, it is generally preferred to employ a single septum so as to maintain the volume of the deflated/folded balloon (and thus the outer capsule) as small as possible.
  • the valve system is preferably attached to the inner surface of the balloon such that a shear force greater than 9 lbs (40 N) is required to dislodge the valve system.
  • a silicone head and opacity ring of a self-sealing valve system can be employed, as can a wedge-shaped septum.
  • an inoculation spacer is preferably incorporated to guide a needle into the self-sealing valve for injection of liquid activation agent into the lumen of the balloon and to prevent the needle from penetrating the wall of the deflated/folded balloon elsewhere such that pressure within the lumen of the balloon cannot be maintained.
  • the inoculation spacer also facilitates preventing liquid activation agent from penetrating the inner container or the folded balloon material, thereby focusing the activation agent in an appropriate manner to properly mix the reactants for C0 2 generation according to the criteria described above.
  • the inoculation spacer is generally in the form of a tube or cylinder.
  • the inoculation spacer is preferably attached to the inner container and/or the self-sealing valve system with an adhesive or other fixing means; however, in certain embodiments the inoculation spacer can be "free-floating" and maintained in position by the folding or rolling of the walls of the balloon.
  • the inoculation spacer can comprise any suitable material that can be passed after separation, erosion, degradation, digestion, and/or dissolution of the outer container; however, preferable materials include non-metallic materials with a minimum Shore D durometer of 40 or more, any metallic material, or a combination thereof.
  • a cupped needle stop (inoculation spacer) can be employed in preferred embodiments.
  • the volume-occupying subcomponent is filled with a fluid using tubing which is subsequently detached and pulled away from the volume-occupying subcomponent.
  • One end of the volume-occupying subcomponent has a port connected to tubing of sufficient length that when unwound can span the entire length of the esophagus, from mouth to stomach.
  • This tubing is connected to the volume-occupying subcomponent with a self-sealable valve or septum that can tear away from the volume- occupying subcomponent and self-seal once the volume-occupying subcomponent is inflated.
  • a physician or other health care professional secures one end of the tubing as the patient swallows the device.
  • the physician uses the tube to transmit a fluid, such as air, nitrogen, SF 6 , other gas(es), vapors, saline solution, pure water, a liquid or vapor under external ambient conditions (e.g., room temperature) that forms a vapor or gas, respectively, at in vivo temperatures (e.g., SF 6 ), or the like, into the volume-occupying subcomponent and thereby inflate it.
  • a fluid such as air, nitrogen, SF 6 , other gas(es), vapors, saline solution, pure water, a liquid or vapor under external ambient conditions (e.g., room temperature) that forms a vapor or gas, respectively, at in vivo temperatures (e.g., SF 6 ), or the like, into the volume-occupying subcomponent and thereby inflate it.
  • the fluid may be or include a variety of other fluid or non- fluid materials as well, including physiologically acceptable fluids, such as aqueous fluids, e.g., water, water with one or more additives (e.g., electrolytes, nutrients, flavorants, colorants, sodium chloride, glucose, etc.), saline solution, or the like.
  • physiologically acceptable fluids such as aqueous fluids, e.g., water, water with one or more additives (e.g., electrolytes, nutrients, flavorants, colorants, sodium chloride, glucose, etc.), saline solution, or the like.
  • the tube may be released in a number of manners.
  • the tubing may be detached by applying a gentle force, or tug, on the tubing.
  • the tubing may be detached by actuating a remote release, such as a magnetic or electronic release.
  • the tubing may be released from the volume-occupying subcomponent by an automatic ejection mechanism.
  • Such an ejection mechanism may be actuated by the internal pressure of the inflated volume-occupying subcomponent.
  • the ejection mechanism may be sensitive to a specific pressure beyond which it will open so as to release any excess pressure and simultaneously release the tube. This embodiment provides a desirable feature through combining release of the tubing with a safety valve that serves to avert accidental over inflation of the volume-occupying subcomponent in the patient's stomach.
  • This automatic release embodiment also provides the benefit that the device inflation step may be more closely monitored and controlled.
  • Current technology allows for a self-inflating intragastric volume-occupying subcomponent which generally begins to inflate in a four minute timeframe after injection with an activation agent such as citric acid.
  • the volume- occupying subcomponent may, in some instances, begin to inflate prior to residing within the stomach (e.g., in the esophagus), or, in patients with gastric dumping syndrome or rapid gastric emptying, the volume-occupying subcomponent may end up in the small intestine prior to the time that inflation occurs.
  • volume- occupying subcomponent may also be advantageous for the volume- occupying subcomponent to inflate gradually or in several steps over time, or for the volume- occupying subcomponent to maintain a volume and/or internal pressure within a preselected range. For example, if gas escapes the volume-occupying subcomponent prior to the desired deflation time, it can be beneficial for the device to re-inflate in order to preserve it in its expanded state.
  • An intragastric balloon system that is manually inflated by a miniature catheter can be employed in certain embodiments.
  • the system preferably remains "swallowable.”
  • the balloon for delivery is in a compacted state and is attached to a flexible, miniature catheter, preferably no larger than 4 French (1.35 mm) in diameter.
  • the catheter is designed such that a portion of the catheter can be bundled or wrapped upon itself for delivery with the encapsulated balloon, allowing the patient to swallow both catheter and balloon for delivery to the stomach.
  • the balloon can contain a self-sealable valve system for attachment of the catheter and inflation of the balloon once it reaches the stomach cavity.
  • the proximal end of the catheter can be left just outside of the patient's mouth, permitting connection to an inflation fluid container that can house the preferred inflation fluid (gas or liquid). After inflation the catheter can be detached from the balloon valve and pulled back through the mouth.
  • This method allows for the intragastric balloon to maintain its swallowability but allow for inflation by a fluid source or a mixture of fluid sources via the catheter.
  • a more rigid, pushable system can be employed wherein the balloon valve is compatible with either the swallowable, flexible catheter or the pushable, rigid catheter assembly.
  • the inflation catheters (swallowable or administrator-assisted pushable) described herein are configured to deliver the balloon device orally and without any additional tools.
  • the administration procedure does not require conscious sedation or other similar sedation procedures or require endoscopy tools for delivery.
  • other versions of the device can be used in conjunction with endoscopy tools for visualization or can be adapted such that the balloon device can be delivered nasogastrically as well.
  • the proximal end of the inflation catheter is connected to a valve or connector that allows for connection to the inflation source or the disconnect source, this is preferably a Y-arm connector or inflation valve.
  • the connector materials may consist of polycarbonate or the like and can connect to a single or multi-lumen catheter tube.
  • the distal end of the inflation catheter is connected to the universal balloon valve of the balloon that has been compacted and housed within a gelatin capsule or compacted using gelatin bands.
  • the catheter tube is preferably from 1 French (0.33 mm) to 6 French (2 mm) in diameter.
  • the catheter is preferably long enough to extend out past the mouth (connected to the inflation connector or valve) and transverse the esophagus down to at least the middle of the stomach - approximately 50-60 cm. Measurement ticks can be added to the tubing or catheter to aid in identifying where the end of the tube is located. Timing for inflation can be initiated by having the tube contain a pH sensor that determines a location difference between the esophagus (pH 5- 7) and the stomach (pH 1-4) based on the different pH between the two anatomical sources, or can be derived or verified from the expected pressure in a contained (i.e., esophagus) versus a less-constrained space (i.e., stomach).
  • the tube can also contain nitinol that has a tunable transmission to the body temperature, taking into account the timing for swallowing.
  • the tube can also be connected to a series of encapsulated or compacted balloons on a single catheter. Each can be inflated and released separately. The number of balloons released can be tune-able to the patient's needs and desired weight loss.
  • the intragastric balloon or catheter is located or tracked in the body by sensing a magnetic field of a magnetizable component of both or either devices, as discussed in detail below.
  • a catheter with the balloon at the distal end is employed to temporarily and firmly hold the balloon in place.
  • a small deflated balloon catheter can be positioned through the head of the gastric balloon (e.g., a "balloon within the balloon"), and then inflated with air during delivery to firmly hold the capsule and balloon in place and prevent spontaneous detachment of balloon from the catheter.
  • This balloon catheter can incorporate a dual channel that can also allow the bigger gastric balloon to be inflated (by gas or liquid). Once the gastric balloon has been satisfactorily inflated, the small air balloon catheter can be deflated and pulled out of the valve (allowing the valve to self seal), and out of the body, leaving the inflated gastric balloon in the stomach.
  • the catheter may be coated to enhance swallowability or is impregnated or treated with one or more local anesthetics or analgesics to ease swallowing.
  • anesthetics may include anesthetics in the amino amide group, such as articaine, lidocaine and trimecaine, and anesthetics in the amino ester group, such as benzocaine, procaine and tetracaine.
  • analgesics may include chloraseptic.
  • a swallowable dual lumen catheter has two lumens with a diameter of the complete assembly no larger than 5 French (1.67 mm), preferably no larger than 4 French (1.35 mm).
  • the inner lumen preferably does not exceed 3 French (1 mm) and functions as the inflation tube, and the outer lumen preferably does not exceed 5 French (1.67 mm) and functions as the disconnection tube; the inner and outer lumen do not exceed 2 French (0.66 mm) and 4 French (1.35 mm), in diameter, respectively.
  • the catheter assembly is connected to a needle assembly, described in more detail below, at the distal end and to a dual port inflation connector at the proximal end.
  • the tubing that the catheter assembly employs is flexible for swallowability, is kink resistant, can withstand body temperature, is resistant to acid, and is biocompatible as the tube transverses the alimentary canal into the stomach cavity.
  • the tube materials are preferably soft and flexible and have moderate tensile strength and a significant amount of hoop strength to handle applied pressures.
  • the lumens are preferably round and co-axial and free-floating so as to provide flexibility.
  • the dual lumen assembly also preferably requires no adhesive or glue.
  • Alternative lumen configurations can include two D-lumens or a combination of a D-lumen and round lumen, and can be used in stiffer configurations of the final catheter assembly.
  • Preferred materials for the tubing include a thermo-resistant polyethylene tubing such as PEBAX® or a thermo-resistant polyurethane tubing such as PELLETHANETM, PEEK or Nylon.
  • the tubing can also be manufactured out of bioresorbable materials such as polylactic acid (PLA), poly-L-aspartic acid (PLAA), polylactic/glycolic acid (PLG), polycaprolactone (PCL), DL-lactide-co-s-caprolactone (DL-PLCL) or the like, wherein the tube can be released after inflation and detachment and swallowed as normal.
  • the inner lumen or inflation tube is attached to the needle assembly that is used to puncture the balloon's self-sealing valve, preferably located at one of the apexes of the balloon housed inside of a gelatin capsule as outer container.
  • the outer lumen is connected to the needle sleeve and provides connection force between the catheter assembly and balloon providing the tensile strength to withstand balloon inflation pressures, e.g., pressures of up to 10 psi or higher, while maintaining the assembly together.
  • the needle sleeve is configured to mechanically couple with the balloon valve assembly.
  • the needle is preferably made of metal, preferably stainless steel or the like, with a maximum size of 25 gauge (0.455 mm), preferably no smaller than 30 gauge (0.255 mm) for inflation timing purposes.
  • the needle sleeve is preferably a soft material such as nylon or the like, or can also be polycarbonate, polyethylene, PEEK, ABS or PVC.
  • the needle sleeve covers the length of the needle in its entirety, such that the body is protected from the needle and the needle can only pierce the balloon septum.
  • the needle sleeve is flush or extends out slightly more than the needle length.
  • the needle is inserted into the balloon septum prior to swallowing and maintains a retention force of approximately 0.33 lb (0.15 kg) when coupled to the silicone area of the balloon valve.
  • the needle sleeve is preferably slightly bell shaped or contains a circular relief or lip so that when inserted into the silicone area of the valve a lock and key mechanism is created to increase the tensile strength of the assembly and enhance the sealing for inflation.
  • the catheter assembly is connected to a Y-adapter assembly preferably made of polycarbonate.
  • the y-adapter is "keyed" so that the inflation gas and connection fluid are connected to the catheter assembly appropriately and travel down the correct lumen.
  • priming of the disconnection lumen may be employed using a liquid.
  • the outer lumen is first flushed with 2 cc of water, saline, DI water or the like prior to balloon inflation.
  • the inflation source container is attached to the connector leading to the inner lumen.
  • the inflation source container works on the premise of the ideal gas law and a pressure decay model.
  • the device is designed to equalize such that a higher starting pressure is used to inflate the balloon than is the resulting end pressure of the balloon.
  • the starting pressure and volume are dependent upon the gas formulation selected, as well as the length of the catheter and the starting temperature (typically ambient temperature) and ending temperature (typically body temperature).
  • the balloon After inflation, the balloon is detached from the catheter assembly using hydraulic pressure.
  • a syringe filled with water, DI water, or preferably saline is attached to the female end of the Y-assembly.
  • the syringe contains 2 cc of liquid and when the syringe plunger is pushed in, enough hydraulic pressure is exerted such that the needle is ejected from the balloon valve.
  • a single lumen catheter can be employed that does not exceed 2 French (0.66 mm) in diameter.
  • the needle/needle sleeve assembly is similar in design to that of the dual lumen catheter described herein. However, with the single lumen system, the distal end of the catheter lumen connects to the needle sleeve only and there is no second catheter inside. Instead, a single thread attached to a needle hub runs co-axially the length of the catheter to aid in tensile strength for detachment and overall flexibility.
  • the needle sleeve is slightly bell shaped or contains a circular relief or lip so that when inserted into the silicone area of the valve a lock and key mechanism is created to increase the tensile strength of the assembly, enhance the sealing for inflation, and since this is a single lumen assembly, the lip increases the force required to remove the needle from the valve so this does not occur haphazardly during the inflation process.
  • the proximal end of the catheter is connected to a 3 -way valve and uses a method of exclusion for inflation and detachment of the balloon.
  • the distal end of the catheter contains the needle sleeve, which is made of nylon or other similar source.
  • the needle is metallic and preferably stainless steel.
  • the tubing that the catheter assembly employs is flexible for swallowability, is kink resistant, can withstand body temperature, is resistant to acid, and is biocompatible as the tube transverses the alimentary canal into the stomach cavity.
  • the tube materials are preferably soft and flexible, preferably co-axial, and resistant to necking or buckling or kinking.
  • the catheter tubing is preferably made of PEBAX®, but can also comprise bioresorbable materials such as PLA, PLAA, PLG, PCL, DL-PLCL or the like, wherein the tube can be released after inflation and detachment and swallowed as normal.
  • the wire inside the catheter tubing attached to the needle is preferably a nylon monofilament, but Kevlar or nitinol wire or other suitable materials can also be used.
  • the distal end of the catheter is attached to the balloon capsule where the needle protrudes through the self-sealable valve.
  • the container is swallowed and a portion of the inflation catheter remains outside of the mouth.
  • the inflation source container is connected to the proximal 3 -way valve, where the port for inflation gas is chosen by excluding the other ports.
  • the inflation fluid (preferably compressed nitrogen gas or a mixture of gases) travels down the single catheter lumen, whereby the inflation gas selects the path of least resistance, or more specifically through the needle cavity and into the balloon.
  • the balloon is preferably inflated in less than 3 minutes.
  • a stiff-bodied inflation catheter can be employed, which can be placed orally or trans-nasally.
  • This system can be from 1 French (0.33 mm) to 10 French (3.3 mm), preferably 8 French (2.7 mm) in diameter.
  • a larger diameter is typically preferred to enhance pushability, with wall thickness also contributing to pushability and kink resistance.
  • the length of the tube can be approximately 50-60 cm.
  • measurement ticks can be added to the tubing to identify where the end of the tube is located, or a pH or pressure sensor on the catheter can be employed to detect location of the balloon.
  • This system for inflation/detachment is similar to the dual lumen system described above, but with a larger needle sleeve to accommodate the larger diameter tube.
  • Materials that can be used in the lumen include, e.g., expanded polytetrafluoroethylene (EPTFE) for the outer lumen and polyetheretherketone (PEEK) for the inner lumen.
  • EPTFE expanded polytetrafluoroethylene
  • PEEK polyetheretherketone
  • a strain relief device can be added to the distal and proximal ends. It is particularly preferred to have strain relief at the distal end, e.g., 1 to 8 inches, preferably 6 inches, to ensure the catheter bypasses the larynx and follows into the esophagus.
  • the proximal end can have strain relief as well, e.g., to ensure fit of the Y-arm.
  • the preferred material for the strain relief is a polyolefin.
  • the method for inflation/detachment is the same method as for the dual lumen configuration where the outer lumen connects to the needle sleeve and the inner lumen connects to the needle.
  • the patient can swallow water or other suitable liquid so as to distend esophageal tissue for smooth passage down of the device. Patients can also be administered an anesthetic at the back of the throat to numb the area and lessen the gag reflex.
  • the tube can also be connected to a series of encapsulated or compacted balloons on a single catheter such that a total volume of up to 1000 cc or more can be administered, as necessary. Each can be inflated and released separately. The number of balloons released can be tunable to the patient's needs and desired weight loss.
  • a catheter can be used for administering a gastric balloon that is similar to balloon catheters used in angioplasty termed "over- the- wire" or rapid exchange catheters.
  • over- the- wire or rapid exchange catheters.
  • the stiff catheter - or physician assisted catheter can slide over the flexible catheter and the balloon can be pushed down in the same manner as the physician-assisted catheter.
  • Different materials can be used to provide the varying degrees of flexibility or one material that is fabricated with different diameters across the length to vary the degree of stiffness can be used.
  • the swallowable self-inflating balloon construction method and the swallowable inflation tube construction method both remove the requirement for endoscopy to place the balloon and make the balloon administration process less invasive. This also allows for the total volume to be placed in a patient to be "titratable,” or adjustable. When a balloon is placed for 30 days, a patient may report that over time they lose their feeling of fullness without eating. To compensate, another balloon can be placed easily without sedation and endoscopy. When a non-deflatable balloon is to be removed endoscopically, it is desirable to color-code the balloon composite walls with different colors so that the physician has a visual marker for removing the balloon at the end of its useful life while keeping the balloon that has remaining useful life in the patient's stomach.
  • the balloon wall can be marked approximately 180° from the self- sealing valve such that when the balloon is punctured endoscopically it folds more efficiently on itself so as to facilitate removal of the thin-walled structure without causing esophageal perforations and/or other damage by the balloon due to its shape, stiffness, and/or thickness of the wall material.
  • the inflation fluid container is employed to control the amount or volume of fluid placed inside of the balloon.
  • This can be in the form of a canister of, e.g., PVC, stainless steel, or other suitable material.
  • the container can also be in syringe form.
  • the materials employed are able contain a fluid, preferably in gas form, e.g., compressed or non-compressed N 2 , Ar, 0 2 , CO 2 , or mixture(s) thereof, or compressed or non-compressed atmospheric air (a mixture of N 2 , 0 2 , Ar, C0 2 , Ne, CH 4 , He, Kr, H 2 , and Xe).
  • the balloon composite wall materials and respective diffusion gradients and gas permeability characteristics are used to select a fluid for inflation of the intragastric balloon, so as to provide a desired volume profile over time for the inflated balloon.
  • the inflation fluid container materials are selected to ensure no or minimal diffusion or leakage of the fluid before it is connected to the y-arm connector or valve of the inflation catheter.
  • the inflation fluid container preferably incorporates a pressure gauge and a connector. It can also contain a smart chip that notifies the healthcare professional of whether inflation is successful or if the balloon should be detached due to an error in the system.
  • the catheter is placed in the mouth/esophagus. Timing of inflation is can be selected so as to minimize time in place.
  • the outer container-catheter assembly once swallowed, takes approximately 4-8 seconds to reach the stomach.
  • the Inflation source container can be attached to the valve or port of catheter system. Inflation timing can be controlled by selecting the length of catheter, diameter of the catheter tube, the starting temperature, and the starting pressure.
  • the amount of starting volume/pressure can be derived, where temperature is controlled inside the inflation source container to match that of the body. It is desired to have an inflation time after swallow of less than 5 minutes, and preferably 2-3 minutes, before balloon detachment and catheter withdrawal.
  • the inputs use to derive inflation of the balloon include inflation container volume, type of inflation fluid (preferably a compressed gas or compressed gas mixture), starting pressure, catheter length and diameter, and desired end volume and pressure of the balloon.
  • the inflation source container provides feedback to the end user based on a pressure decay system. Where there is an expected starting pressure and expected ending pressure to indicate whether the balloon is inflated properly, there is no need for endoscopic visualization.
  • Each scenario of expected pressure outputs can have its own tolerances around it to reduce possibilities of false positives, and the inflation fluid container can provide feedback based on these tolerances as to the status of balloon inflation and detachment. This is derived based on the Ideal Gas Law, where there is an expected end pressure based on the fixed volume of the balloon.
  • the pressure remains high and doesn't decay as expected, this can indicate a failure in the system (e.g., the balloon container did not dissolve, the balloon is expanding in the esophagus because there is, e.g., a kink in the tube or other failure in the catheter system).
  • the starting pressure is 22 PSI to inflate a balloon to 250 cc and 1.7 psi (0.120 kg/cm 2 ) for a nylon-based material.
  • a math chip can be added to the inflation source container that provides at least one of a visual, audible, or tactile notification, or otherwise transmits a notification to a healthcare professional or administrator of whether inflation is successful or if there is an error in the system based on the pressure curve and a set of predetermined pressure tolerances and expected timing of inflation.
  • an inflation canister that has at least two reservoirs (one large and one small) and at least two gauges, with one or more valves that allow for selection of gas release into the second reservoir or into the balloon itself.
  • the larger reservoir can contain the total amount of fluid required to fill the balloon. A small amount of fluid can be released from the larger reservoir into the smaller reservoir first to determine the location of the balloon and its readiness for full inflation.
  • the gauge reads back a medium pressure level (e.g., 1-4 psi), this indicates that the balloon is in a constrained space, such as the esophagus or duodenum, and should not be inflated.
  • a medium pressure level e.g., 1-4 psi
  • the balloon catheter's feedback as read on the gauge is approximately 1 psi, this indicates that the balloon is in the stomach and ready to be inflated. If the feedback is at 0 psi, this indicates is a leak in the balloon valve catheter system and that the device should be retrieved.
  • the balloon can be filled based on a starting pressure by using a spring mechanism, a balloon-within-balloon mechanism, or other pressure source. These mechanisms can potentially result in more predictable/consistent pressure decay curves, and again can have accompanying, predetermined tolerances for feedback back to the end user.
  • the materials selected for the composite wall of the balloon may be optimized to maintain the original inflation gas without significant diffusion, or may also allow for diffusion of the gases located in the gastric environment, e.g., C0 2 , 0 2 , argon, or N 2 to diffuse through the wall of the balloon to inflate, partially or wholly, once the balloon is placed in the stomach.
  • a fluid a liquid or gas
  • a gastric balloon inflated by nitrogen, C0 2 gas, a single fluid (gas) or a mixture of gasses employs a composite wall that provides barrier properties (fluid retention), properties imparting resistance to pH and moisture conditions in the gastric environment or the environment within the central lumen of the balloon, and structural properties to resist gastric motility forces, abrasion of the balloon wall in vivo, and damage during manufacturing and folding of the balloon.
  • Certain materials employed in the balloon materials are able to withstand a hostile gastric environment designed to break down foreign objects (e.g., food particles).
  • the wall materials meet biocompatibility requirements and are constructed such that the total thickness of the wall (barrier material) is thin enough to be compacted and placed inside of a swallowable-sized container ("outer container”) without significant damage or lodging.
  • the outer container is small enough to transcend the esophagus (which has a diameter of approximately 2.5 cm).
  • the wall or barrier material is also heat formable and sealable for balloon construct and maintains a bond strength that can contain internal gas pressures of up to 10 psi generated by the initial inflation pressure as well as pressure due to the ingress of gas molecules from the stomach cavity until the system's gas environment reaches stasis.
  • the film properties that are evaluated to determine suitability for use in the composite wall of the balloon include pH resistance, water vapor transmission rate, gas barrier properties, mechanical strength/abrasion properties, temperature resistance, formability, flex-crack (Gelbo) resistance, surface energy (wettability) compliance, and heat bond potential.
  • the various layers in the composite wall can impart one or more desirable properties to the balloon (e.g., C0 2 retention, resistance to moisture, resistance to acidic environment, wettability for processing, and structural strength).
  • a list of polymer resins and coatings that can be combined into a multi-layer preformed system (“composite wall") is provided in Tables la-b. These films can be adhesively bonded together, co-extruded, or adhered via tie layers or a combination thereof to obtain the desired combination of properties for the composite wall, as discussed below.
  • the materials identified as film coatings in Tables la-b are provided as coatings applied to a base polymer film, e.g., PET, Nylon, or other structural layer. Table la.
  • a blended polymer resin using multiple layers is employed to maintain the inflated balloon's shape and volume by retaining the inflation fluid for the duration of the intended use.
  • Certain barrier films can advantageously be employed for this purpose in the composite wall of the balloon.
  • the barrier materials have a low permeability to carbon dioxide (or other gases, liquids, or fluids that are alternatively or additionally used to inflate the volume- occupying subcomponent).
  • These barrier layers preferably have good adherence to the base material.
  • Preferred barrier coating materials and films include polyethylene terephthalate (PET), linear low density polyethylene (LLDPE), ethylene vinyl alcohol (EVOH), polyamides such as Nylon (PA) and Nylon (PA polyimide (PI), liquid crystal polymer (LCP), high density polyethylene (FIDPE), polypropylene (PP), biocompatible poly(hydroxyamino ethers), polyethylene naphthalate, polyvinylidene chloride (PVDC), saran, ethylene vinyl alcohol copolymers, polyvinyl acetate, silicon oxide (SiOx), silicon dioxide (S1O 2 ), aluminum oxide (AI 2 O 3 ), polyvinyl alcohol (PVOH), nanopolymers (e.g., nanoclay), polyimide thermoset film, EVALCA EVAL EF-XL, Hostaphan GN, Hostaphan RHBY, RHB MI, Techbarner HX (SiOx- coated PET), Triad Silver (silver metalized PET), Oxyshield 24
  • Alternative gas-barrier materials include polyamine-polyepoxides. These materials are typically provided as a solvent-based or aqueous-based thermosetting composition and are typically spray-coated onto a preform and then heat-cured to form the finished barrier coating.
  • Alternative gas barrier materials that can be applied as coatings to the volume- occupying subcomponent include metals such as silver or aluminum.
  • Other materials that may be used to improve the gas impermeability of the volume occupying subcomponent include, but are not limited to, gold or any noble metal, PET coated with saran, and conformal coatings.
  • One method that is used in the packaging industry to delay diffusion of the inflation fluid is to thicken the material. Thickening the material is generally not preferred, as the total composite wall thickness preferably does not exceed 0.004 inches (0.010 cm) in order for the balloon to be foldable into the desired delivery container size for swallowing by a patient.
  • a multilayer polymer film that is able to withstand the gastric environment over the course of the usable life of the balloon includes linear low density polyethylene (LLDPE) adhesively bonded to a Nylon 12 film.
  • LLDPE linear low density polyethylene
  • an additional film layer with barrier properties, such as PVDC can be added to the composite wall.
  • the layers providing gas barrier properties are preferably situated as inner layers in the composite wall as they are less mechanically robust than resins that are considered "structural” such as Nylon and the like.
  • Layers such as polyurethane, Nylon, or polyethylene terephthalate (PET) can be added to the composite wall for structural purposes, and are preferably placed as outermost (proximal to the gastric environment or proximal to the central lumen of the balloon) layers, provided that the pH resistance of such layers can withstand the acidic environment of the stomach or the central lumen of the balloon.
  • Other layers may in addition or alternatively be included.
  • the various layers of the composite wall need not be situated in any particular order, but those of superior resistance to acidity, temperature, mechanical abrasion, and superior biocompatibility profile are preferably employed as layers contacting the gastric environment. Those with superior resistance to, e.g., acidity and temperature, are preferably employed as layers contacting the central lumen of the balloon.
  • the various layers of the wall can include a single layer or up to 10 or more different monolayers; however, a film thickness of from 0.001 inches (0.0254 cm) to 0.004 inches (0.010 cm) thick is desirable such that the resulting balloon compacted to fit into a swallowable capsule.
  • the resulting composite wall preferably has good performance specifications with respect to each category listed in Tables la-b.
  • Films that are co-extruded are advantageously employed, as some adhesives may contain leachables that are undesirable from a biocompatibility perspective.
  • coextrusion allows for better blending such that the materials maintain their original properties when combined in this fashion and are less likely to be subject to delamination when exposed to gastric motility forces.
  • Combining films with similar properties, e.g., two film layers with excellent gas barrier properties, in a composite wall is advantageous for use in a gastric balloon containing nitrogen, oxygen, C0 2 or a mixture thereof as the inflation gas or where the external environment the product is to be placed in, contains a mixture of gases including C0 2 , e.g., the stomach.
  • a primary advantage of such composite films is that restrictions on film thickness can be observed without sacrifice of gas barrier properties.
  • Such a configuration also contributes to reducing the effects of processing damage (e.g., manufacturing and compacting) and damage due to exposure to in vivo conditions (e.g., gastric motility forces).
  • the composite wall includes a plurality of layers.
  • the first layer is an outer protective layer that is configured for exposure to the gastric environment. This layer is resistant to mechanical forces, exposure to water (vapor), abrasion, and high acidity levels.
  • Nylon or more specifically, Nylon 12 is particularly preferred for the layer exposed to the gastric environment, and is especially resistant to mechanical forces.
  • polyurethane is RF welded to saran to yield a 6- 7 mil thick composite wall.
  • a five layer system comprising a layer of saran sandwiched between two polyurethane layers. Between the saran layer and each of the polyurethane layers is a tie layer. The layers can be welded together, co-extruded or adhered using an adhesive. This tri-layer is then co-extruded to Nylon on each side, and then a final sealing layer (polyethylene or the like) is added to one of the nylon layers for the total composite wall.
  • a representative example of material combinations that are commercially available or manufacturable is provided in Table 2. The orientation of the layers (innermost - in contact with the central balloon lumen, or outermost - in contact with the gastric environment) is also indicated if more than two layers are described to support a suggested composite wall.
  • film resins listed in Table 2 provide some degree of gas barrier properties. Therefore, many can be used solely to form the balloon wall as a monolayer film; however they can also be used in conjunction with other film resins to meet the desired gas retention and mechanical specifications for the useful life of the balloon based on the inflation gas and external environment the balloon is to be placed in. These film resins can also be coated with gas barrier coatings listed in Tables la-b. Additional film layers can be added to form the total composite wall. While such additional layers may not impart substantial barrier properties, they can provide structural and/or mechanical properties, protection for the other layers of the composite wall that are susceptible to water vapor, humidity, pH, or the like, or other desirable properties.
  • the film layers can be assembled using various adhesives, via co-extrusion, via lamination, and/or using tie layers and such to create a composite wall that meets the requirements of an intragastric balloon suitable for use for at least 25 days, or up to 90 days or more, with the specified gas retention properties.
  • Table 2 provides a list of layers and layer combinations suitable for use in composite walls for an intragastric balloon. The composite description, resin abbreviation, configuration (single layer, bilayer, trilayer, or the like) and trade name of commercially available combinations are listed.
  • the number of layers indicated does not include any adhesive layers or tie layers used to fabricate the composite wall, such that a 6- layer composite wall may, for example, have two or three adhesive layers and/or tie layers that make up the total composite wall, and therefore the total number of layers can be eight or nine in final form.
  • layer is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a single thickness of a homogenous substance (e.g., a coating such as SiOx, or a layer such as PET, or a uniform polymeric blend), as well as to a supporting layer having a coating thereon (wherein a “coating” is, e.g., a material typically employed in conjunction with substrate that provides structural support to the coating layer).
  • a PET-SiOx "layer” is referred to herein, wherein a layer of Si-Ox is provided on a supporting PET layer.
  • a forward slash is used to indicate a boundary between layers of the specified chemistries.
  • the boundary can be a discontinuity, or can be a tie layer, adhesive layer, or other layer separating the layers of recited chemistry.
  • the composite wall has a thickness of 0.005 inches or less (5.0 mil or less); however, in certain embodiments a thicker composite wall may be acceptable. Generally it is preferred that the composite wall have a thickness of no more than 0.004 inches (4.0 mil).
  • the intragastric volume-occupying device may comprise a torsion spring component capable of expanding the device to a specific volume upon deployment of the device in a patient's stomach.
  • the torsion spring component is a wire coiled in the middle and having two outwardly extending arms that engage the walls inside of the volume occupying device.
  • the arms of the torsion spring may be connected to the arms of additional torsion springs in order to provide the inside walls of the device with multiple points of engagement.
  • the coiled segment of the spring may be configured to apply a pressure consistent with the force required to maintain a particular volume of the device over a long period of time with little or no stress to the spring.
  • the coiled segment may be attached to the device from within the device.
  • the coiled segment is wrapped around a mounting post or arbor within the center of the device while the device is in a pre-deployment state.
  • the center post or arbor may accommodate the compressed coiled segment of the spring.
  • the mounting post may be constructed using a polymer material or metal.
  • the center post is removed from the device once deployed, thereby releasing the torsion spring and allowing the spring to expand within the device.
  • the torsion spring may be comprised of an alloy exhibiting the characteristics of a "shape memory" metal (SMA) including TiNi (Nitinol), CuZnAl, and FeNiAl alloys.
  • SMA shape memory metal
  • the torsion spring may also be comprised of any metal that does not pose a significant risk to health when exposed to humans, including but not limited to, steel alloy, stainless steel, and titanium.
  • the torsion spring component Prior to deployment of the device, the torsion spring component may be compressed to allow the device to be reduced in size, thereby allowing insertion of the device into a patient's stomach.
  • the device is wrapped with a "belt" that holds the torsion spring in a compressed state until deployment of the device.
  • the center mounting post holds the center coil segments of a plurality of attached torsion springs in a compressed state.
  • the intragastric volume-occupying device may comprise a shape memory polymer (SMP) capable of expanding the device, from within the device, to a specific volume upon deployment of the device in a patient's stomach.
  • SMP shape memory polymer
  • the SMP may take on an original shape of a hemispherical ring 21, the size of which is manufactured to expand the device 20 to a particular volume allowed by the device when the SMP is relaxed.
  • the ring aspect may allow the SMP to be deformed into a temporary smaller shape to allow for deployment and removal of the device in a patient.
  • the SMP may comprise additional rings, for example, two or more intersecting rings, or an open honeycomb network, or another foldable spring structure.
  • the SMP may be compressed or bent into a temporary smaller shape to allow for insertion into an intragastric volume-occupying device, and thereby allow the intragastric device to be inserted into a patient's stomach without the need for surgery.
  • the SMP may make use of the thermal shape-memory property of shape memory polymers.
  • An SMP with a transition temperate (ti) can be compressed at room temperature or lower temperature. It will stay compressed until the SMP reaches a temperature greater than ti. It can then expand to its original shape.
  • the SMP may be designed to re-form from its compressed state to its original state when heated above some threshold temperature or after removal of a mechanical stress (e.g., one or more biodegradable compression straps or "belts" which hold the device and SMP in a compressed state).
  • a mechanical stress e.g., one or more biodegradable compression straps or "belts" which hold the device and SMP in a compressed state.
  • the SMP may be activated and allowed to expand to its larger original shape when triggered by the patient's body heat or the mechanical stress is released. After activating the shape memory of the SMP by temperature increase or release of the mechanical stress, it would assume its original shape. This may allow the SMP to expand the intragastric device to a size that will prevent the patient's body from passing the device through the digestive system in the event that the device would otherwise become deflated or reduced in size.
  • the SMP is rigid below body temperature for ease of insertion, and after warming to body temperature becomes soft to reduce patient discomfort and complications.
  • the SMP may be compressed through the use of reducing temperature of the SMP material or through mechanical stress. While a soft, flexible SMP is preferred for removal, certain classes of shape-memory polymers possess an additional property: biodegradability.
  • biodegradability In one exemplary embodiment of a biodegradable SMP, once the device is ready for removal, the device can be sliced into smaller, removable pieces and the SMP material may be left behind to degrade into substances which can be eliminated by the body. Thus the device may be removed without the necessity for a surgery to remove the SMP.
  • the intragastric volume-occupying device may comprise one or more umbrella-like structures to prevent the device from leaving the stomach.
  • the structure may comprise one or more struts 11 attached to a base focus point 12 on the device 10, and biased from a collapsed position to an expanded position by foldable sections that extend between the struts or between the strut and the device when the struts are in their expanded position, but which are folded between the struts or between the strut and the device when the struts are in a collapsed position.
  • the struts are a straight linear shape, and are fully expanded once the struts are made parallel to an arbitrary line tangential to the base focus point outside of the device.
  • the struts may be located inside the intragastric device and curved so that they are concave or convex in relation to the curvature of the interior lining of the device.
  • the intragastric volume-occupying device may comprise a one way self-sealing valve that can allow a needle or catheter to breach the device, from outside the device, in order to expand the device with a gas, liquid, solid, or any combination thereof.
  • a one way self-sealing valve that can allow a needle or catheter to breach the device, from outside the device, in order to expand the device with a gas, liquid, solid, or any combination thereof.
  • one or more umbrella-like structural devices Prior to the device expansion, one or more umbrella-like structural devices may be collapsed within the device to allow for introduction to the stomach.
  • the struts and foldable sections may be comprised of a rubber or polymer capable of tolerating a low ph. environment.
  • the struts and foldable sections may further be comprised of an SMP material.
  • the SMP structure may utilize a transition temperature (ti) lower than body temperature in order to maintain a collapsed state until the intragastric volume-occupying device and the device contained SMP structure are introduced to the stomach.
  • the SMP structure can then expand to its original shape allowing the struts to fully extend from the device and the foldable sections to expand.
  • two SMP structures may be based within the device at opposite ends of the device on a common plane perpendicular to the device's axis, allowing the two extended SMP structures to form two half circle or dome shapes consistent with the shape of the device, supporting the complete spherical shape of the device.
  • the SMP structure may be activated and allowed to expand to its larger original shape when triggered by the patient's body heat and the introduction of matter used to fill the device from the catheter or needle.
  • the SMP structure is rigid and collapsed at a temperature below that of the body for ease of insertion, and after warming to body temperature becomes soft to reduce patient discomfort and complications.
  • a mechanical stress is employed to keep the umbrella-like structure in a collapsed state.
  • the mechanical stress may be comprised of a biodegradable material safe for human ingestion.
  • the low ph. of the environment quickly dissolves the mechanical stress, allowing the structure to fully expand.
  • the struts themselves may comprise the foldable section, wherein a plurality of struts are attached to the base of the structure and extending to a common connection point.
  • the strut combination will resemble the petal of a flower.
  • a plurality of the sets of struts may extend from the base focus point of the device, having a distance between them and creating a circular area of expansion.
  • the umbrella-like structure may also be comprised of a biodegradable SMP. This allows for the removal of the device without the need to remove the fully extended SMP structure.
  • the device can be sliced into smaller, removable pieces and the SMP material may be left behind to degrade into substances which can be eliminated by the body. Thus the device may be removed without the necessity for a surgery to remove the SMP. Hydraulic Scaffold
  • the intragastric volume-occupying device may comprise one or more collapsible structures that, once expanded, may prevent the device from leaving the stomach.
  • the structure may comprise one or more struts 31 attached to a number of positions 32 within the device 30, and may be biased from a collapsed position to an expanded position upon release of hydraulic pressure provided by an external liquid hydraulic apparatus. Upon expansion, the sections of the structure may extend between fixed points inside the device, pushing the walls of the device outward.
  • the struts may be located inside the intragastric device and curved so that they are concave or convex in relation to the curvature of the interior lining of the device.
  • the intragastric volume-occupying device may comprise balloon containing a foldable ring within the first balloon.
  • a ring 41 is provided comprising, e.g., a shape-memory alloy, e.g., a copper-aluminum-nickel alloy or a nickel-titanium alloy (e.g., nitinol), or a shape-memory polymer.
  • shape-memory polymers include polyurethanes, polyurethanes with ionic or mesogenic components made by prepolymer method.
  • block copolymers also show the shape-memory effect, such as, block copolymer of polyethylene terephthalate (PET) and polyethyleneoxide (PEO), block copolymers containing polystyrene and poly(l,4-butadiene), and an ABA triblock copolymer made from poly(2-methyl- 2-oxazoline) and polytetrahydrofuran.
  • a linear, amorphous polynorbornene (Norsorex, developed by CdF Chemie Nippon Zeon) or organic-inorganic hybrid polymers consisting of polynorbornene units that are partially substituted by polyhedral oligosilsesquioxane (POSS) also have shape-memory effect.
  • a crosslinked polyurethane can be made by using excess diisocyanate or by using a crosslinker such as glycerin, trimethylol propane. Introduction of covalent crosslinking improves in creep, increase in recovery temperature and recovery window.
  • PolyEthyleneOxide-PolyEthyleneTerephthalate (PEO-PET) block copolymers can be crosslinked by using maleic anhydride, glycerin or dimethyl 5-isophthalates as a crosslinking agent. The addition of 1.5 wt% maleic anhydride increased in shape recovery from 35% to 65% and tensile strength from 3 to 5 MPa.
  • FIG. 4B shows the ring of FIG. 4A folded in half 42
  • FIG. 4C shows the ring folded in quarters 43.
  • the folded ring 43 can be placed in a device 40 and assumes its original shape 41 in vivo.
  • the intragastric volume-occupying device may comprise a first balloon containing one or more additional balloons within the first balloon.
  • the first balloon may be a spherical, cylindrical, or pear shaped container housing a balloon sharing the same shape.
  • the first balloon may also comprise an elongated plug with a self-sealing fill valve allowing a needle or catheter to penetrate the first balloon and provide an outside source or vacuum of matter.
  • the matter may be comprised of a gas, liquid, or solid matter to expand the first balloon cavity.
  • the material of the first balloon may generally allow for flexibility and expansion of the material while resisting the degrading effects of the gastric environment.
  • the first balloon may be made of a material such as linear low density polyethylene, polydimethyl siloxane, polytetrafluro ethylene, poly ethylene, poly propylene, poly amide, or any combination thereof.
  • FIGS. 6A-B illustrate a device 60, which comprises an outer balloon 61 and an inner balloon 62 filled through a valve 63.
  • the inner balloon is filled with fluid or gas via the valve, and does not contact the inner surface of the outer balloon 61.
  • the inner balloon could be inflated via a self-inflation technology (a C0 2 generating chemical such as sodium bicarbonate activated with an acid such as acetic acid or hydrochloric acid) as described in U.S. Patent No. 6,981,980, U.S.
  • the inner balloon may be configured to disconnect from the valve after filling, or, e.g., as in a self-inflating balloon, be entirely or wholly disconnected from the outer balloon and float freely in the outer balloon, or attached to an inner surface at one or more points by, e.g., an adhesive or weld.
  • FIGS. 6C-D describe a balloon wherein instead of an inner spherical or elliptical balloon, there is an inflatable cylinder 64 or an inflatable donut/hemispherical ring.
  • Such inner balloons can also be configured to detach from the valve after inflation or be self- inflated.
  • the balloons are inflated separately; however, in some embodiments inflation of the primary balloon initiates filling of the secondary balloon, or vice versa.
  • the inner balloon can utilize different materials from the outer balloon, or materials that do not require resistance to the extreme environment of the stomach in vivo as the outer balloon is exposed to; however, in certain embodiments in can be desirable to utilize the same materials for the inner and outer balloons, e.g., for ease of fabrication.
  • the secondary balloon is configured to be sufficiently large to prevent entry into the duodenum if the primary balloon deflates.
  • the first balloon contains within it a second balloon.
  • the second balloon may be a structure wholly independent of the first balloon, or it may be integrated with the first balloon entirely or only partially.
  • the second balloon will contain an amount of a first reactive material as the first and second balloons are introduced to the stomach. Once introduced to the stomach, the first balloon may be filled using the elongated plug with a second reactive material that will pass through the external wall of the second balloon, causing the first reactive material to expand due to the added material.
  • the elongated plug and self-sealing valve of the first balloon may extend to the second balloon. This can allow the first balloon and second balloon to be inflated with a gas, liquid, or solid simultaneously.
  • the plug as it extends to the second balloon may further comprise a bleed-off valve to prevent over-inflation of the second balloon.
  • the second balloon may be comprised of a shape memory polymer with an original size larger than the opening to the duodenum.
  • the second balloon may also have a one way self-sealing valve to allow gas or liquid to pass into the second balloon and also to prevent matter from escaping.
  • the first and second balloons are deflated or collapsed to allow passage into the stomach without invasive procedures.
  • gas may be passed into the first balloon through the elongated plug.
  • the second balloon will begin to expand to the size of its original shape, using the force of the shape memory polymer to inflate itself through the one way self-sealing valve with the gas being introduced into the first balloon until the second balloon has expanded to its original shape.
  • the amount of first reactive material added to the second balloon is determined based on the size of the opening to the duodenum, the second balloon being inflated to a size that would allow the intragastric volume-occupying device to maintain a size that would prevent passage of the device through the duodenum.
  • the intragastric volume-occupying device may comprise an amount of hydrogel.
  • Pharmaceutically available synthetic hydrogels offer a way to administer biodegradable, three-dimensional networks, which are able to imbibe large amounts of water or biological fluids, and thus resemble, to a large extent, a fabricated shape.
  • Hydrogel can respond to a number of physiological stimuli present in the body, such as pH, ionic strength and temperature.
  • the hydrogel may comprise a network of polymer chains that are hydrophilic, sometimes found as a colloidal gel in which water is the dispersion medium. In the low ph environment of the stomach, glycol chitosan hydrogels or chitosan hydrogels may be used for swelling of the gel.
  • hydrogels can be fabricated into suitable shapes to prevent the device from exiting the stomach.
  • suitable shapes include, but are not limited to, cylindrical, ovoid, spherical, cubic, prism, or cuboid.
  • the shapes may be fabricated to be larger than the pyloric sphincter opening to prevent the passage of the device through the duodenum.
  • the device may be initially inflated using a hydrogel compound that can respond to gastric acid.
  • the gastric fluid may pass through the external walls of the device and causing the hydrogel material within the device to expand.
  • the hydrogel may be fabricated into a predetermined shape and attached to the device.
  • the gastric fluid may activate the fabricated shape and expand it to a size to prevent the device from exiting the stomach.
  • the hydrogel may be shaped initially using a soft gel like coating that will rapidly dissolve in the low pH environment of the stomach.
  • FIG. 7A depicts a device 70 comprising an outer balloon 71 and an internal structure containing or comprising a hydrogel 72.
  • the hydrogel is contacted with a swelling fluid (e.g., water, saline solution, or gastric fluid) via a valve or passageway 73, the valve optionally attached to the hydrogel.
  • a swelling fluid e.g., water, saline solution, or gastric fluid
  • the hydrogel may be free floating or attached to an inner surface of the balloon, and incidentally contact the swelling fluid that enters the outer balloon through the valve or passageway.
  • water is introduced into the balloon during catheter ejection.
  • water vapor in the stomach in vivo diffuses through the wall of the outer balloon and causes the hydrogel to expand.
  • FIGS. 7B-C depict a device 70 comprising an outer balloon and a toroidal-shaped hydrogel component attached to the valve 73.
  • the intragastric volume-occupying device may comprise a plurality of magnets.
  • the interior of the device may be lined with a magnetic surface along both hemispheres.
  • the magnetic surfaces may be arranged so that the magnetic poles of each side are facing each other.
  • the magnetic material on the left hemisphere is arranged so that the magnetic material on the right hemisphere is facing the identical pole on the left side, resulting in the magnetic material on both hemispheres repelling each other.
  • FIG. 8 depicts a device 80 containing magnetic material 81 situated on opposite sides of the device and having a same pole alignment, e.g., both north pole aligned or both south pole aligned.
  • the outer balloon 82 includes a hemispheric weld 83. If the outer balloon deflates, the magnetic repulsion forces prevent the balloon volume from reducing enough to enter the duodenum.
  • the intragastric volume-occupying device may comprise a pressure sensor within the device.
  • the pressure sensor can be used to monitor pressure within the device to determine whether the device is leaking.
  • the pressure sensor within the device may communicate pressure data wirelessly to an external sensor.
  • the external sensor can communicate with the pressure sensor by sending an energizing signal to the pressure sensor and adjusting the phase and frequency of the signal to determine a phase difference between the sent signal and the signal received from the pressure sensor.
  • the energizing signal sent from the external sensor may be coupled to the pressure sensor via magnetic coupling.
  • the external sensor may collect and provide data to the patient in real time over a graphical user interface (GUI) such as a touch screen or a computer program.
  • GUI graphical user interface
  • FIG. 9 deipicts a system wherein a balloon 90 is equipped with a fill valve 95 and a miniature pressure sensor 91 embedded in, attached to, or free-floating in the balloon 90.
  • the patient is provided with a wearable patch 52 that wirelessly communicates with the pressure sensor through the patient's body.
  • a graphical user interface 93 on a receiver or other device 94 that communicates wirelessly or via wired connection with the patch 92 actively monitors the internal balloon pressure and notifies the patient when pressure reaches a preselected level, e.g., a level indicative of pressures in the intragastric space rather than different pressures indicative of the inflated balloon, indicating balloon failure.
  • the intragastric volume-occupying device may comprise a safety tether or an anchor to prevent a malfunctioning device from leaving the stomach.
  • the safety tether may comprise a physical tether to maintain a consistent device location.
  • the tether may be connected to an anchor secured to a tooth.
  • An anchor may be designed around the tooth and glued into place, with a tether between the anchor and the device.
  • the tether may reach up to the nasal cavity where the anchor may be affixed as a piece of jewelry or temporary clip to a surface within the nasal passage.
  • the intragastric volume- occupying device may comprise a catheter anchor designed to keep the device from leaving the stomach.
  • the catheter anchor may comprise a catheter physically connected to the device and extended through the esophagus, and may exit the body through the mouth or nasal cavity. This may be ideal for a patient who is immobile.
  • the intragastric volume-occupying device may comprise a volute spring.
  • the volute spring may be inside the device. Initially, the spring may be under compression, allowing the device to be reduced in size to a small disk. The two ends of the volute spring may be affixed to either side of the device along a plane perpendicular to an axis through the center of the device. Once the device is introduced to the stomach, the compression of the spring may be released to expand the device to a size that will prevent it from leaving the stomach.
  • the device may have a plurality of volute springs configured to apply outward pressure against the interior walls of the device in order to achieve maximum expansion across the surface area.
  • the intragastric volume-occupying device may comprise a self-regulating micro air pump.
  • the air pump may regulate the pressure per square in within the device, and maintain a constant pressure.
  • the device may contain weight on an end opposite the air pump in order to prevent the air pump from being submerged in stomach fluids.
  • Another example embodiment comprises a small cartridge of compressed gas attached to a one way self-sealing valve of the device.
  • the pressure in the cartridge and the pressure in the device may be equalized so that any pressure lost from the device may be regained from the cartridge.
  • the cartridge may be attached to the device in such a manner that resembles a "tail" in order to avoid leaving the stomach.
  • the intragastric volume-occupying device may comprise a fibrous compound.
  • the compressed device may be introduced to the stomach.
  • a catheter or needle may pierce the bladder to the device and fill the device with an amount of fibrous compound.
  • the fibrous compound may be in the form of a gel or paste containing a density of fibrous material sufficient to block a leak formed in the device.
  • the balloon is preferably thermoformed and sealed such that the edges of the pieces used to form the balloon are overlapping.
  • This can be accomplished by any suitable method. For example, two flat sheets of material can be placed in a frame with magnetized edges to hold the two sheets in place. Slack can be added to the piece of film to orient the material such that it maintains its properties after the thermoforming process.
  • the frame can be placed over a mold that represents a hemisphere the balloon.
  • a heater e.g., a 4520 watt infrared heater
  • a vacuum can be pulled.
  • the material with slack put in it prior to vacuum being applied, reorients the material such that it is more evenly distributed around the hemisphere shape.
  • the material is preferably thickest in the middle and is made thinner on the sides where it will be welded to a second piece to create a sphere or ellipsoid having a substantially uniform wall thickness. For example, starting with a 0.0295" film, the middle of the film or subsequent apex has an ending film thickness of 0.0045" and the edges have an ending thickness of 0.0265" for subsequent overlapping during the welding process.
  • the valve can be adhered to the (e.g., polyethylene, PE) side of one of the hemispheres and protrude out of the opposite (e.g., nylon) side.
  • One hemisphere typically consists of Nylon as the outermost layer and the second hemisphere typically has polyethylene (sealing web) as the outermost layer.
  • the edges of the two hemispheres are preferably aligned such that they overlap by at least 1 mm and no more than 5 mm. Alignment and overlay of the two hemispheres is done to compensate for the thinning at the edges during the thermoforming process, which in turn inhibits seam bursts in vivo.
  • each half of the spheroid is placed on a fixture and the excess from the thermoforming process is trimmed.
  • the sealing layer a PE or similar layer is bonded to the sealing layer of the second film half.
  • the film of the hemisphere that has the nylon exposed to the external environment is folded up along the edges of the sphere on one half such that it can be bonded to the hemisphere with the polyethylene on the outermost layer.
  • the two film pieces are then sealed using a roller bonder or a band heater.
  • the air provides the compression
  • the heater provides the sealing heat
  • a motor that moves the bonder around the area controls the time that is required to ensure proper sealing.
  • the band heater there is a heating element, an expandable plug that provides the compression, and a timer.
  • the band is a metal, preferably copper and a spool-like fixture provides the compression needed. Using film layers of different melt temperatures helps ensure integrity of the barrier layers of the final balloon configuration. If two similar materials are welded, then an insulator can be employed.
  • one sphere is provided with the Nylon layer facing out and the second sphere has a PE layer facing out.
  • the largest percentage of intragastric balloon malfunctions is due to spontaneous deflations.
  • Spontaneous deflations can occur due to (1) external puncture of the intragastric balloon due to gastric motility forces, (2) over inflation of the balloon due to increased internal pressure of the balloon from uptake of the gastric environment of the gasses and water vapor and (3) under inflation of the balloon that leads to fatiguing of the excess material and subsequent puncture of the balloon.
  • the balloon system can be tailored to ensure it remains inflated throughout its useful life. Instances of spontaneous deflation in this intragastric balloon can be minimized by selection of the starting inflation gas in conjunction with selection of the composite wall materials and construction.
  • Selection of the permeability characteristics with respect to water vapor transmission and gas permeability of the composite wall so as to take advantage of the properties of the gastric space contents can enable the rate of diffusion of gases into and out of the balloon to be controlled. This method allows for a tunable method for prevention of under inflation and over inflation.
  • stomach accommodation Another phenomenon seen with gastric balloons and obesity in general is stomach accommodation.
  • the stomach grows to accommodate the space occupying device or excess food that is ingested.
  • the volume of a stomach containing an intragastric balloon grows over time, such that the patient becomes hungrier.
  • the balloon size can also be increased over time by selecting the starting inflation gas(es) and water and other in vivo gas permeability characteristics of the film so as to maintain weight loss.
  • selecting the permeability characteristics of the composite wall in conjunction with the starting gases and utilizing the transfer of gases and water inside of the balloon from the gastric environment the balloon can be designed to grow over its useful life in response to stomach accommodation.
  • stomach environment consists of water, acid (hydrochloric acid), a mixture of gases, and chyme (the semifluid mass of partly digested food expelled by the stomach into the duodenum).
  • Stomach gas usually arises from swallowing air during eating.
  • the composition of air is nitrogen (N 2 ) 78.084%; oxygen (0 2 ) 20.9476%; argon (Ar) 0.934%; carbon dioxide (C0 2 ) 0.0314%; neon (Ne) 0.001818%; methane (CH 4 ) 0.0002%; helium (He) 0.000524%; krypton (Kr) 0.000114%; hydrogen (H 2 ) 0.00005%; and xenon (Xe) 0.0000087%.
  • Gastric pC0 2 closely parallels local (splanchnic) arterial and draining venous blood pC0 2 values.
  • Neutralization of stomach acid can also generate gas.
  • the stomach acid reacts with bicarbonates (e.g., as are present in certain antacids) in the digestive juices, the chemical process creates C0 2 , which is normally absorbed into the blood stream. Digestion of food in the intestines, mainly through fermentation by colonic bacteria, generates C0 2 , H 2 , and methane.
  • Microbes appear to be the sole source of all of the hydrogen and methane produced in the intestine. These arise from fermentation and digestion of nutrients (polysaccharides from fruits and vegetables are not digested in the small intestines). Small quantities of a few other gases, including hydrogen sulfide, indoles, and ammonia can also be generated.
  • the composition of the initial fill gas is substantially characteristic of the composition of the mixture of gases in the in vivo gastric environment.
  • Such an initial fill gas can include only N 2 and C0 2 , or can include only N 2 , C0 2 , and 0 2 , or can include N 2 and C0 2 as well as one or more other gases present in the in vivo environment (e.g., water vapor, H 2 , CH 4 , Ar, H 2 S, or NH 3 ).
  • Argon or another inert gas (or inert gases) can be substituted in part or in whole for N 2 , which is considered an inert gas in the context of the preferred embodiments.
  • the initial fill gas comprises from about 75% v/v to about 96% v/v N 2 , from about 5% v/v to about 15% (vol.) 0 2 , and from about 1% v/v to about 10% v/v C0 2 , more preferably from about 80% (vol.) to about 85% (vol.) N 2 , from about 5% (vol.) to about 13% (vol.) 0 2 , and from about 4% (vol.) to about 8% (vol.) C0 2 .
  • the initial fill gas comprises from about 4% (vol.) to about 8% (vol.) C0 2 , with the remainder N 2 or another inert gas. In embodiments wherein the initial fill gas comprises other gases in addition to C0 2 and the inert gas(es), it is preferred that the initial fill gas comprises from about 4% (vol.) to about 8% (vol.) C0 2 .
  • Controlled self-inflation of the intragastric balloon in the in vivo environment can be achieved by using a semi-permeable or permeable composite wall in the balloon and initially filling the balloon with a preselected single gas, such as N 2 or 0 2 .
  • the balloon utilizes differences in concentrations of gases and water concentration differences between the internal balloon environment and the external environment in vivo (Gl/stomach) to increase and/or decrease the volume and/or pressure over time.
  • a wall can be employed that has a relatively higher permeability to the single gas used to inflate the balloon than to other gases present in the in vivo gastrointestinal environment.
  • the volume and/or pressure in the balloon will decrease as nitrogen diffuses out into the in vivo environment through the oxygen permeable wall.
  • oxygen gas is employed as the inflation gas
  • the volume and/or pressure in the balloon will decrease as oxygen diffuses out into the in vivo environment through the oxygen permeable wall.
  • the differential in partial pressure of the single gas in the balloon (higher) versus the in vivo environment (lower) will drive the process until equilibrium or homeostasis is reached.
  • a wall can be employed that has a relatively lower permeability to the single gas used to inflate the balloon than to other gases present in the in vivo gastrointestinal environment.
  • nitrogen gas is employed as the inflation gas
  • the volume and/or pressure in the balloon will increase as C0 2 , and all of the other gases present in the gastric environment, diffuse into the balloon through the C0 2 permeable wall.
  • the differential in partial pressure of the permeable gas in the balloon (lower) versus the in vivo environment (higher) will drive the process until equilibrium is reached.
  • maintaining and/or controlling inflation of the balloon can also be done using the differences in concentrations between the internal balloon environment and external gastric environment in which the balloon volume/pressure can be increased or decreased as needed to extend the useful life of the product.
  • One reason to decrease the pressure can be to first inflate the balloon with a large, but highly diffusible/soluble gas molecule such as C0 2 in addition to a more inert gas like nitrogen to pre-stretch the balloon, with the soluble gas diffusing out of the balloon and other gases not originally present in the balloon migrating in to fill the balloon.
  • Inflation gases can be selected to start with the majority of the gas in the balloon comprising a large, inert gas or a gas that has low diffusivity through the selected composite wall.
  • inert gases include but are not limited to nitrogen, as well as SF 6 , C 2 F 6 , C 3 F 8 , C 4 Fi 0i C 4 F 8 , C 4 F 8 , C 3 F 6 , CF , and CC1F 2 -CF 3 .
  • An inert gas in conjunction with a less inert gas(es) that are more soluble in the gastric environment, can be combined to comprise the starting balloon inflation gas composition where the inert gas would be in excess to the more soluble/diffusible gas.
  • nitrogen as a more soluble/diffusible gas with a gas of lower diffusivity /solubility such as SF 6 , C 2 F 6 , C 3 F 8 , C 4 Fio , C 4 F 8 , C 4 Fg, C 3 F 6 , CF 4 , and CCIF 2 -CF 3 .
  • a gas of lower diffusivity /solubility such as SF 6 , C 2 F 6 , C 3 F 8 , C 4 Fio , C 4 F 8 , C 4 Fg, C 3 F 6 , CF 4 , and CCIF 2 -CF 3 .
  • a fill gas of certain embodiments can comprise 5% (vol.) of the more soluble/diffusible inert gas in combination with 95% (vol.) of the less soluble/diffusible inert gas (e.g., 5% N 2 in combination with 95% SF 6 ); or 10% of the more soluble/diffusible inert gas in combination with 90% of the less soluble/diffusible inert gas (e.g., 10% N 2 in combination with 90% SF 6 ); or 15% of the more soluble/diffusible inert gas in combination with 85% of the less soluble/diffusible inert gas (e.g., 15% N 2 in combination with 85% SF 6 ); or 20% of the more soluble/diffusible inert gas in combination with 80% of the less soluble/diffusible inert gas (e.g., 20% N 2 in combination with 80% SF 6 ); or 25% of the more soluble/diffusible inert gas in combination with
  • an initial fill gas consisting of 20% of the less soluble/diffusible inert gas with the remainder a more soluble/diffusible inert gas is employed; or an initial fill gas consisting of 19- 21% of the less soluble/diffusible inert gas with the remainder a more soluble/diffusible inert gas is employed; or an initial fill gas consisting of 18-22% of the less soluble/diffusible inert gas with the remainder a more soluble/diffusible inert gas is employed; or an initial fill gas consisting of 17-23% of the less soluble/diffusible inert gas with the remainder a more soluble/diffusible inert gas is employed; or an initial fill gas consisting of 16-24% of the less soluble/diffusible inert gas with the remainder a more soluble/diffusible inert gas is employed; or an initial fill gas consisting of 15-25% of the less soluble/diffusible inert gas with the
  • an initial fill gas comprising 18- 20% SF 6 with the remainder as nitrogen can be employed, or 19-21% SF 6 with the remainder as nitrogen; or 18-22% SF 6 with the remainder as nitrogen; or 17-23% SF 6 with the remainder as nitrogen; or 16-24% SF 6 with the remainder as nitrogen; or 15-25% SF 6 with the remainder as nitrogen.
  • Patient diet and medications can also affect/control balloon inflation status - primarily by C0 2 concentration effects produced in the gastric environment.
  • gastric pH also affects C0 2 concentration.
  • This particular method can also allow for a greater degree of tuning of the device's useful life based on the composite wall material, e.g., barrier/non-barrier and whether the gas that diffuses in is maintained longer in the balloon if it has a barrier wall versus a non-barrier wall.
  • This particular form of self-inflation can be employed using a self- inflating gastric balloon (e.g., initially inflated by a gas generating reaction in the balloon initiated after swallowing), or an inflatable gastric balloon (e.g., inflated using a catheter, with or without endoscopic assistance, delivered nasogastrically or any other delivery method).
  • the method can be used with any gastric balloon, including swallowable balloons and balloons placed in the stomach by, e.g., endoscopic methods.
  • the method is particularly preferred for use in connection with intragastric devices; however, it can also be applied to use in, e.g., pulmonary wedge catheters and urinary incontinence balloon devices.
  • the advantages to this technology include the ability to compensate for stomach accommodation, allowing the balloon to adapt to a stomach that may increase in volume over time, thereby maintaining patient satiety. It also permits starting with a smaller amount of inflation gas constituents for a self-inflating balloon. It can prevent spontaneous deflations by utilizing diffusion gradients between gastric balloon systems and the in vivo gastric environment.
  • a multi-layer co-extruded blend for the wall layers is employed.
  • a particularly preferred configuration is Nylon 12/Ethyl Methyl Aery late/Poly vinylidene Chloride/ Ethyl Methyl Acrylate /Nylon 12/Linear Low Density Polyethylene+Low Density Polyethylene (also referred to as co-extruded Nylon 12-encapsulated PVDC-Nylon 12-LLDPE+LDPE multilayer).
  • Another particularly preferred configuration is a co-extruded multi-layer Nylon 12/Linear Low Density Polyethylene+Low Density Polyethylene.
  • Selection of the resins for the composite wall construction can be varied to control compliance (stretchiness), puncture resistance, thickness, adhesion, sealing bond strength, orientation, acid resistance, and permeability characteristics to gasses and water vapor to achieve a particular effect.
  • the self-inflating (also referred to as automatic inflating) or inflatable (also referred to as manually inflating) intragastric balloon is provided with mechanisms to reliably control timing of deflation.
  • the balloon auto-deflates and passes through the stomach, through the lower gastrointestinal tract, and out of the body at the end of its pre-determined useful life (non-spontaneous), preferably between 30 and 90 days but can be timed to deflate within 6 months.
  • the timing of deflation can be accomplished via the external gastric environment (by conditions of temperature, humidity, solubility, and/or pH, for example) or via the environment within the lumen of the inflated balloon. It is preferable for consistency to control the initiation of the self- deflation process by manipulating the internal balloon environment.
  • the patch applied to allow for inverted seams as described above and/or one or more additional patches or other structures added to the balloon construction are made out of an erodible, degradable, or dissolvable material (natural or synthetic) and are incorporated into the wall of the balloon.
  • the patch(s) are of sufficient size to ensure opening of a sufficient surface area to cause rapid deflation, and to prevent re-inflation by seepage of stomach fluid into the balloon.
  • the balloon patch(s) comprise materials that can be applied to the balloon such that a substantially smooth surface is maintained, and preferably comprise a single layer or multi-layered material.
  • the patch(s) are constructed using an erodible, disintegrable, degradable or other such material that is preferably tissue-compatible and degrades into non-toxic products or is a material that slowly hydrolyzes and/or dissolves over time (e.g., poly(lactic-co-glycolic acid) (PLGA), poly(lactide-co-glycolide) (PLG), polyglycolic acid (PGA), polycaprolactone (PCL), polyesteramide (PEA), polyhydroxyalkanoate (PHBV), polybutylene succinate adipate (PBSA), aromatic copolyesters (PBAT), poly(lactide-co- caprolactone) (PLCL), polyvinyl alcohol (PVOH), polylactic acid (PLA), poly-L-lactic acid PLAA, pullulan, polyethylene glycol (PEG), polyanhydrides, polyorthoesters, polyaryletherketones (PEEK), multi-block polyetheresters, poliglecaprone, polydiox
  • erodible, disintegrable, or degradable materials can be used alone, or in combination with other materials, or can be cast into/co-extruded, laminated, and/or dip coated in conjunction with non-erodible polymers (e.g., PET or the like) and employed in the construction of the balloon.
  • Degradation/erosion occurs, is initiated by, and/or is controlled by the gastric environment (e.g., by conditions of temperature, humidity, solubility, and/or pH, for example), or is controlled within the lumen of the balloon (e.g., by conditions of humidity and/or derived pH, for example) based on what the patch is exposed to. Thickness of the polymer as well as environment which affects degradation and time of exposure can also facilitate degradation timing.
  • Degradation/erosion are timed such that they occur once the pre-determined balloon useful life is completed (e.g., inflation is maintained for from 25 to 90 days in vivo in the stomach before degradation/erosion results in formation of an opening permitting deflation).
  • the patch can comprise a similar fluid retention barrier film or the same film as the remaining wall of the balloon which is adhered to the balloon using a weak adhesive, or welded or adhered such that after a specified amount of time the patch delaminates from the applied area and allows for an opening for inflation fluid release for deflation. Or if deemed necessary for rapid deflation the entire balloon composite wall can be made of the erodible material.
  • the mechanism of using an erodible material or a material that mechanically fails after a pre-specified time is be similar for all embodiments for deflation mechanisms described below as well.
  • the timing of degradation or erosion can be controlled using the external gastric environment (e.g., by conditions of temperature, humidity, solubility, and/or pH, for example) and/or can be controlled by conditions within the lumen of the balloon (e.g., by conditions of humidity and/or pH of residual liquid in the balloon).
  • a plug or plugs can be incorporated into the balloon construction and can consist, all or in part, of an erodible, disintegrable, or otherwise degradable synthetic or natural polymer similar to those described above (e.g., PLGA, PLAA, PEG, or the like).
  • the plug can be formed into various shapes (e.g., cylinder shape) to achieve various surface-to-volume ratios so as to provide a preselected and predictable bulk degradation pattern for the erodible polymer.
  • the plug can incorporate a releasing mechanism that can be chemically initiated after degradation/erosion begins, such that the septum or plug material pops out of the balloon or falls inside of the balloon, thereby creating a passageway for fluid release and subsequent deflation of the balloon.
  • Mechanical additions that can be used in conjunction with a plug include a degradable/erodible/disintegrable material that holds a plug (e.g., of a non-degradable or degradable material) in place or a compressed spring housed within the retaining structure or plug structure. More specifically one preferred embodiment to achieve deflation can comprise a housing, a radial seal, a solid eroding core, and a protective film attached to the external surface of the eroding core.
  • Example materials for each component used to achieve this deflation mechanism can be as follows: Housing: Biocompatible structural material, capable of withstanding enough radial force to form an air tight seal.
  • Possible materials include: polyethylene, polypropylene, polyurethane, UHMWPE, titanium, stainless steel, cobalt chrome, PEEK, or nylon; Radial Seal: The radial seal needs to be composed of a biocompatible elastic material, capable of providing liquid and gas barrier to acidic environments. Possible materials include: silicon, polyurethane, and latex; Eroding Core: The eroding core needs to be a material capable of breaking down at a predictable rate at given environmental conditions. Possible materials include: PLGA, PLA, or other polyanhydrides that are capable of losing integrity over time or any materials listed above that provide erodible characteristics.
  • the spring mechanism once the material degrades, the spring is released and/or the plug/septum is pulled into the balloon or pushed out of the balloon, thus releasing fluid once an orifice has been created by release of the spring mechanism and pushing out or pulling in of the plug.
  • Another preferred embodiment is comprised of a septum, moisture eroding material inside an inlet port, and moisture absorbing expansion material.
  • the eroding materials slowly erode away when exposed to moisture, eventually exposing the moisture absorbing expansion material.
  • the expansion pulls the septum out of position in the head by pushing against a septum lip or a ring attached to the septum. Pulling the septum out of position causes an immediate deflation of the balloon.
  • the expanding material can be sheathed in water blocking materials, such as parylene, as well as slowly water degrading materials.
  • the moisture contact can be controlled by small inlet ports.
  • the inlet ports can be small holes, or a wick material that draws moisture in a controlled manner.
  • the desired deflation time is achieved through a combination of eroding materials, blocking materials, and inlet port sizing.
  • the balloon can incorporate one or more plugs in the wall of the balloon that contain a compressed pellet or gas releasing pellet.
  • the pellet can be comprised of any combination of constituents that, when activated, emit C0 2 gas (e.g., sodium bicarbonate and citric acid, or potassium bicarbonate and citric acid, or the like).
  • the pellet can be in tablet or rod form protected by an erodible, disintegrable, or degradable material that is preferably tissue-compatible and degrades into non-toxic products or that slowly hydrolyzes and/or dissolves similarly to the plugs and patches described above (e.g., poly(lactic-coglycolic acid) (PLGA), polyvinyl alcohol (PVOH), polylactic acid (PLA), poly-L-lactic acid PLAA, Pullulan, Polyethylene Glycol, polyanhydrides, polyorthoesters, polyaryletherketones (PEEK), multi-block polyetheresters, poliglecaprone, polydioxanone, polytrimethylene carbonate, and other like materials).
  • PLGA poly(lactic-coglycolic acid)
  • PVOH polyvinyl alcohol
  • PLA polylactic acid
  • PLA poly-L-lactic acid PLAA
  • Pullulan Polyethylene Glycol
  • polyanhydrides polyorthoesters
  • PEEK polyaryletherketone
  • Degradation/erosion of the plug initiates the reaction of the two chemicals in the pellet and subsequently leads to formation of gas (e.g., C0 2 ). As sufficient gas is trapped or built up, sufficient pressure is eventually generated to push out the softened polymer material and create a larger channel for the C0 2 gas in the balloon to escape. External pressure applied by the stomach to the balloon (e.g., squeezing) can contribute to the process of creating a larger channel. Dimensions and properties of the plug (diameter, thickness, composition, molecular weight, etc.) comprised of the polymer drives the timing of degradation.
  • gas e.g., C0 2
  • plugs or patches of different shapes or sizes similar to those of the plugs described above can be employed within the balloon lumen in a multi-layer configuration including a semi-permeable membrane to facilitate balloon deflation.
  • the plug or patch is made of similar degradable/erodible/dissolvable material as described above (e.g., poly(lactic-co-glycolic acid) (PLGA), polyvinyl alcohol (PVOH), polylactic acid (PLA), PLAA, pullulan, and other like materials) and contains a compartment enclosed by a semi-permeable membrane (impermeable to an osmolyte) that contains a concentrated solution of a solute or osmolyte (such as glucose, sucrose, other sugars, salts, or combination thereof).
  • a semi-permeable membrane impermeable to an osmolyte
  • a concentrated solution of a solute or osmolyte such as glucose, sucrose, other sugars, salts, or combination thereof.
  • the water molecules move by osmosis down the water gradient from the region of greater water concentration to the region of lower water concentration across the semi-permeable membrane into the hypertonic solution in the compartment.
  • the compartment containing the osmolyte swells and eventually bursts, pushing the membranes and the degraded plug or patch out, thereby allowing rapid gas loss through the newly created channels or areas.
  • a balloon composed of a septum, moisture eroding material inside an inlet port, and moisture absorbing expansion material is employed.
  • the eroding materials slowly erode away when exposed to moisture, eventually exposing the moisture absorbing expansion material.
  • the expansion pulls the septum out of position in the head by pushing against a septum lip or a ring attached to the septum. Pulling the septum out of position causes an immediate deflation of the balloon.
  • the expanding material can be sheathed in water blocking materials, such as parylene, as well as slowly water degrading materials. The moisture contact can be controlled by small inlet ports.
  • the inlet ports can be small holes, or a wick material that draws moisture in a controlled manner.
  • the desired deflation time is achieved through a combination of eroding materials, blocking materials, and inlet port sizing.
  • Another mechanism for self-deflation is to create a forced de-lamination scheme, which can provide a larger surface area to ensure rapid deflation.
  • the outermost layer is substantially strong enough to hold the inflation fluid (e.g., polyethylene terephthalate (PET) or the like), the middle layer is comprised entirely of an erodible material (e.g., PVOH or the like) while the inner layer is comprised of a weaker material (e.g., polyethylene (PE) or the like).
  • PET polyethylene terephthalate
  • the PET or outermost layer is "scored" or hatched with erodible material to create small channels that erode over time. This creates channels such that the gastric fluid seeps into the balloon layers and starts degrading the fully erodible material.
  • the material that composes the innermost layer When the erodible layer degrades or dissolves, the material that composes the innermost layer also erodes, degrades or dissolves since it is not strong enough to withstand the gastric forces/environment on its own. The balloon then collapses on itself and eventually passes through the lower gastrointestinal tract. Having an erodible layer sandwiched between a strong and weak layer facilitates timing of erosion by creating a longer path length than an erodible plug or patch affected by the gastric environment. The distance between scores or openings can also be selected so as to provide a desired deflation rate.
  • the composite wall of the entire balloon or a section of the composite wall includes several material layers that are slowly penetrated by water that has been injected inside the balloon during the manufacturing process or during the inflation process. This water penetrates through the layers, eventually reaching a material that substantially expands, rupturing a thin external protective later, and creating a large hole for gas to escape and the balloon to deflate.
  • the water expanding material is protected from liquid via a coating or sheath, such as parylene, which allows a controllable amount of moisture exposure. Once water reaches the expansion material, it exerts a force on the protective outer layer, causing it to rupture.
  • the outer layer may be created with a weakened bonding area, a partially scored area, or other methods of ensuring a desired rupture location and to facilitate desired timing for auto- deflation to take place.
  • Each material layer can have different erosion rates (e.g., fast or slow) and can be selected by the predetermined time deflation is desired to occur (e.g., after 30 days, 60 days, or more). By varying the number, thickness, and rate of each of the circumferential layers, the time to deflation can be accurately controlled.
  • a pressure sealing button that is adhesively bonded over a perforation in the balloon material can be provided for deflation.
  • the adhesive bonding the button erodes over time when it comes into contact with moisture derived from the gastric fluid or that has been injected inside the balloon. Once the adhesive can no longer bond and create an airtight seal between the adhesive and the button, the balloon will rapidly deflate. By controlling the hole size and moisture exposure of the adhesive, the erosion time can be accurately predicted.
  • Deflation can also be facilitated by creating a series of connecting ports within the septum or on another similar structure attached to the balloon composite wall.
  • the ports can be constructed using a water- or acid-dissolving, biologically compatible, low permeability substance, such as gelatin.
  • the diameter of the hole, number of holes, channel width, and channel length can all be adjusted to control the dissolving parameters.
  • the port/channel layout design can ensure that only a small amount of surface area is exposed to moisture at any particular time, thereby controlling the rate of erosion and ultimately deflation.
  • a mechanism to facilitate passing involves an erosion mechanism that allows for the balloon to be broken down into a size that has a higher probability of predictably passing through the lower gastrointestinal system.
  • the size of the balloon as deflated is less than 5cm long and 2 cm thick (similar to various foreign objects of similar size that have been shown to pass predictably and easily through the pyloric sphincter). This can be accomplished by providing the balloon with "erodible seams.” One seam that breaks the balloon open into (at a minimum) two halves, or more seams are provided so that a plurality of smaller balloon pieces is produced in the dissociation reaction.
  • the number of seams used can be selected based on the original surface area of the balloon and what is required to dissociate the balloon into pieces that are of a size that can predictably pass through the gastrointestinal tract more easily.
  • the rate of seam erosion can be controlled by using a material affected by, e.g., the external gastric environment pH, liquid, humidity, temperature, or a combination thereof.
  • Seams can be single layer consisting of only erodible material, or multi-layer.
  • the timing of self-deflation can be further controlled by the design of the seam layers, e.g., making the reaction and/or degradation of the seam material dependent on the internal environment of the balloon instead of the external environment.
  • any impact of person-to-person gastric variability (pH, etc.) that can affect erosion timing is minimized.
  • the internal balloon environment can be manipulated by adding excess water at injection to create a more humid internal environment, or the amount of constituents added can be varied to manipulate the pH, etc.
  • a composite wall having a permeability of ⁇ 10 cc/m 2 /day is generally preferred; however, depending upon the desired effect of inflation and re-inflation by in vivo gasses such as C0 2 , a higher permeability of >10 cc/m /day in in vivo conditions can be desirable.
  • each of the films in the table can be suitable for use in various selected embodiments, such that the resulting balloon wall has a permeability to C0 2 of even greater than >10 cc/m 2 /day, e.g., >50 cc/m 2 /day, >100 cc/m 2 /day, >200 cc/m 2 /day, >300 cc/m 2 /day, >400 cc/m 2 /day, >500 cc/m 2 /day, >750 cc/m 2 /day, >1000 cc/m 2 /day, >1500 cc/m 2 /day, >2000 cc/m 2 /day, >2500 cc/m 2 /day, >3000 cc/m 2 /day, >3500 cc/m 2 /day, or even >4000 cc/m 2 /day.
  • Table 3 and elswhere herein, various films are listed. When the film comprises two or more layers, a "/" is used to indicate a layer of one material adjacent to another layer, optionally with intervening layers or materials.
  • A/B/C would refer to a film comprising a layer of A adjacent to a layer of B, and the layer of B adjacent to a layer of C on an opposite side of layer B from the side adjacent to layer A, with or without intervening layers or materials (e.g., tie layers, adhesives, surface preparations, surface treatments, or the like).
  • PE/EVOH/PE refers to a film comprising a first layer of polyethylene adjacent to a layer of ethylene vinyl alcohol, and the layer of ethylene vinyl alcohol adjacent to a second layer of polyethylene on an opposite side of the ethylene vinyl alcohol to that adjacent to the first layer of polyethylene.
  • KuraristerTM C 3 mil 0.003 UNK 0 3.2
  • the devices configured to prevent entry of the device into the duodenum if the primary balloon deflates are optionally employed in combination with a further device that indicates leakage or deflation of the balloon. Upon indication of leakage or deflation, the balloon may then be retrieved, e.g., endoscopically, from the stomach.
  • the balloon deflates and emits a sensory stimulant that is configured to trigger a response by one of the patient's senses.
  • the device may emit an odor that is smelled by the patient.
  • the device may emit a taste that is tasted by the patient.
  • the device may emit a coloring agent that the patient can visually see after passing the agent, for example in a toilet.
  • the sensory stimulant may cause a physiological response indicative of deflation.
  • the deflated balloon may emit a substance that encourages passage through the bowels.
  • flavorants may be used to indicate deflation to the patient. Theses may be the same or different as the flavoring agents that may be used in some embodiments, for example with the ingestible event markers for a voltaic or pH based locating system. Thus, flavorants such as peppermint, oil of wintergreen, cherry flavoring or the like can also be used. Additionally, it may be desirable to add a coloring agent to make the dosage form more attractive in appearance or to help identify the product.
  • the intragastric balloon comprises a Proteus® Digital Health Feedback System. It includes an ingestible sensor or sensors.
  • the ingestible sensor is fabricated from food grade materials and is activated upon contact with gastric fluids.
  • the sensor includes no battery and no antenna; instead, it is powered by components in gastric fluids and transmits a unique number generated by the sensor upon activation.
  • the Proteus Physiologic Sensing Platform is a technology platform that allows development of products and tools to capture, analyze, and transmit physiologic data about the user. The platform is actively used to develop consumer wellness and medical monitoring devices.
  • the development framework and manufacturing environment support the development of a full range of medical and consumer devices.
  • the platform enables the development of products that: Capture Real Time Physiologic Data; Process and Store Captured Data; Wirelessly Transmit Data; Monitor and Set Alerts; Are Comfortable to Wear; and Are Very Low Cost.
  • the sensor can be inserted into the balloon and be allowed to move freely within the balloon. Alternatively, it can be attached to an inner wall of the balloon.
  • the sensor may be incorporated in a the balloon in an unencapsulated form as received from the manufacturer, or can be provided with a suitable aqueous or gastric-fluid soluble encapsulation, e.g., a gelatin coating or polysaccharide coating, or it can be enclosed in an envelope or other coating comprising a material with a resistance to moisture or water having a pH close to neutral, but minimal resistance to acidic gastric fluid.
  • a suitable aqueous or gastric-fluid soluble encapsulation e.g., a gelatin coating or polysaccharide coating
  • an envelope or other coating comprising a material with a resistance to moisture or water having a pH close to neutral, but minimal resistance to acidic gastric fluid.
  • the latter embodiment can be desirable in certain intragastric balloons having a degree of permeability to water, wherein over time water vapor/moisture can accumulate in the interior of an intact balloon, to offer protection to the sensor prior to its activation by acidic gastric fluids
  • Biomarkers can be utilized in connection with the intragastric device in certain embodiments to detect failure of the device.
  • biomarker or “biological marker” refer to a broad subcategory of medical signs - that is, objective indications of medical state observed from outside the patient - which can be measured accurately and reproducibly.
  • Biomarkers can include almost any measurement reflecting an interaction between a biological system and a potential hazard, which may be chemical, physical, or biological. The measured response may be functional and physiological, biochemical at the cellular level, or a molecular interaction.” Examples of biomarkers include everything from pulse and blood pressure through basic chemistries to more complex laboratory tests of blood and other tissues.
  • the intragastric system incorporates a substance in its interior that provokes a physiological process in a patient, and the result of that process is a detected biomarker indicating failure of the device.
  • the intragastric device can contain a substance, e.g., a harmless virus or bacteria or component thereof that triggers antibody production. Detection of the antibody indicates device failure (e.g., a leak or deflation permitting escape of the substance).
  • the balloon could also incorporate a drug or other chemical that induces a physiological change, e.g., adrenaline inducing a rapid heart rate, ethanol that produces ethyl glucuronide upon release into the body where it is metabolized, or the like.
  • the biomarker can be detected using a suitable detection device. For example, if a rapid heart rate, elevated skin temperature, or perspiration is the biomarker, a wearable device, e.g., an activity tracker such as a FitBit or similar device can be employed. Alternatively, in the case of a metabolic product in a body fluid (blood, urine), a colorimetric or electrochemical test strip can be employed. Other sensors are known for use in connection with breath or perspiration.
  • a physical symptom as a biomarker, e.g., for example, laxatives (e.g., phenolphthalein) and emetics (e.g., apomorphine, xylazine, hydrogen peroxide).
  • laxatives e.g., phenolphthalein
  • emetics e.g., apomorphine, xylazine, hydrogen peroxide.
  • tracer compounds can be advantageously employed. These can fall into one or more general categories in terms of the alerting effect: smell/odor, taste/flavor, or visual.
  • smell as an alerting effect, a small amount of mercaptan gas can be incorporated in the balloon's fill gas.
  • Such substances when released, will emit a foul odor, e.g., in a burp or other release of gases from the gastrointestinal system, but be otherwise physiological inactive.
  • Suitable substances include methyl mercaptan, benzyl mercaptan, butyl mercaptan, ethyl mercaptan, skatole, butyric acid, butyric anhydride, cadaverine, putrescine, or the like.
  • Such substances are advantageously of an aroma not normally encountered in connection with food, beverages, or normal bodily functions. Desirably, such substances are detectable at very low levels (e.g., parts per billion by weight) and are either gaseous or volatile.
  • Substances that can produce a detectible taste include vanillyl butyl ether, allyl isothiocyanate, piperine, capsaicin, allicin, or diallyl disulfide.
  • flavorants include diacetyl, isoamyl acetate, benzaldehyde, cinnamaldehyde, ethyl propionate, methyl anthranilate, limonene, ethyl decadienoate, allyl hexanoate, ethyl maltol, ethylvanillin, and methyl salicylate.
  • Bitterants can advantageously be employed, such as denatonium, sucrose octaacetate, quercetin, brucine, or quassin.
  • substances that can produce a color in urine can advantageously be employed.
  • the active ingredients in vitamins or certain foods (such as asparagus) that cause urine odor can be incorporated as a tracer, as can certain supplements (e.g., fish oils).
  • substances that are otherwise detectable in urine can be employed.
  • substances for detection by visual or other analysis of urine include, for example, betacyanin (red food coloring), indican (precursor to indigo blue), indigo carmine (used in urologic surgery), riboflavin vitamin B2 (bright yellow), methylene blue (used as a placebo in pills), trypan blue, congo red, brilliant blue, Eosin Y, Erythrosine B, Fast Green FCF, iodine, safranin, triamterene, amtrip, cascara chloroquine ferrous salts, dextran, levodopa, methocarbamol, methyldopa, metronidazole, nitrates, nitrofurantoin, quinine, sulfonamides, bismuth, chlor
  • heptamethine dyes or dyes detectable upon contact with near-IR light are desirable.
  • the substance produces a color detectable by the unaided human eye, e.g., in the range of visually detectable frequencies.
  • the substance can produce a color outside of this frequency range, e.g., detectable by application of ultraviolet light, or that are naturally fluorescent.
  • Substances that can impart a sensation upon urination or defecation can also be employed, e.g., capsaicin or other such substances that impart a burning sensation.
  • a tracer When a tracer is employed in the intragastric balloon, it can be incorporated in any suitable form. Gas tracers can be added to the fill gas mixture. Liquids can be injected in liquid form into the balloon. Solids can be provided as pellets, powders, e.g., pulverized solids or lyophilized powers, or the like.
  • the device can incorporate a radio-frequency identification (RFID) device.
  • RFID radio-frequency identification
  • Such devices use of electromagnetic fields to transfer data, for the purposes of automatically identifying and tracking tags attached to or included/imbedded within objects.
  • the tags contain electronically stored information. Some tags are powered by electromagnetic induction from magnetic fields produced near the reader. Some types collect energy from the interrogating radio waves and act as a passive transponder.
  • the RFID tag is a passive tag that is used in conjunction with an active reader.
  • the intragastric balloon can incorporate a passive RFID tag on one side of the balloon and a counterweight on the other. For a balloon in an inflated state, the RFID tag will be positioned at the top of the stomach. Upon deflation, the RFID tag will be expected to fall to the bottom of the stomach.
  • a second RFID tag can be incorporated on an opposite side of the balloon. Detection of the RFID tags in a spaced apart configuration can suggest that the balloon is inflated, while a close spacing can indicate possible deflation.
  • magnets are secured on opposite sides of the balloon. In an inflated state, the magnets will be spaced apart. Upon deflation, the magnets can be held in proximity to each other by their magnetic fields. By detecting the change in magnetic characteristics for the spaced apart versus paired configuration, deflation can be detected. Similarly, a wire or other conductive trace can be incorporated in the balloon wall. Deflection of the wire can be detected by a strain gauge, or other sensor, suggesting deflation of the device.
  • the proportions and amounts of each agent may be manipulated such that the inflation reaction stops prior to exhaustion of all of one of the agents. The remaining quantity of agent will thereby function as a weight in the volume-occupying subcomponent.
  • various other elements of the inflation subcomponent may be designed to ultimately serve as a weight, e.g. the capsule or other retaining element that otherwise serves to separate the reactive agents may also provide a weighting function after inflation.
  • one or more solids or liquids produced as reaction byproducts may serve to weigh or orient the volume-occupying subcomponent. As illustrated in FIGS.
  • the volume-occupying subcomponent 400 encloses a solid component in pellet form 132, the component being soluble in gastric fluid.
  • gastric fluids can enter and exit the balloon, solubilizing the component and permitting it to enter the gastric space.
  • Amounts of dyes as discussed herein providing a suitable effect in an intragastric balloon can be as low as 10 mg or less; however, higher amounts can also be employed, e.g., 15 mg, 20 mg, 25 mg, 30, mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 150 mg, 100 mg, 200 mg, or higher.
  • An amount of from about 15 mg to about 60 mg is typically employed, e.g., about 20-40 mg, e.g., about 30 mg. Similar amounts can also be employed for the other dyes identified herein.
  • the dye can be injected into the balloon in a liquid form, e.g., a pure liquid or, e.g., a solution, emulsion, or suspension in a suitable liquid, e.g., water, ethanol, mineral oil, vegetable oil, or any other physiological acceptable liquid or combination thereof, alone or in combination with other pharmaceutically acceptable excipients, e.g., components to assist in solubilizing or forming a stable emulsion or suspension of the dye.
  • a suitable liquid e.g., water, ethanol, mineral oil, vegetable oil, or any other physiological acceptable liquid or combination thereof
  • other pharmaceutically acceptable excipients e.g., components to assist in solubilizing or forming a stable emulsion or suspension of the dye.
  • it can be provided in a solid form, e.g., a paste, a pellet, granules, powder, encapsulated form, or any other suitable form, either in a pure state or in combination with other pharmaceutically acceptable ex
  • the dye can be placed in the balloon at the time of manufacture, e.g., a pellet or powder of the dye is placed in the balloon, or a coating of the dye is applied to an interior wall or other structure in the balloon.
  • the dye can be placed in the balloon by a physician or other individual administrating the balloon to a patient after manufacture, e.g., prior to, concurrent with, or after inflation in vivo.
  • biomarkers such as certain dyes
  • Liquid biomarkers may form vapors which contaminate the ambient environment. Gaseous biomarkers may diffuse into the environment, contaminating nearby structures. Solid forms may also present a contamination risk.
  • methylene blue powder has the tendency to blow into the air and attach itself to nearby surfaces.
  • dry, powdered dyes tend to stick to a worker's gloves, such as when being measured out or otherwise prepared.
  • the biomarker can be packaged into an easily used, premeasured quantity.
  • small amounts (e.g., aliquots) of the biomarker in liquid or solid form can be encapsulated into one or more dissolvable capsules, such as premanufactured gelatin capsules.
  • a gelatin or other biocompatible coating material as described herein can be applied to a pellet or other solid form so as to encase the biomarker pellet in a conformal or encapsulating coating.
  • one or more of the capsules is placed within the balloon.
  • the capsule can be advantageously placed near the valve so as to facilitate folding of the balloon, e.g., so as to minimize the size of the uninflated balloon prior to encapsulation before swallowing.
  • the encapsulated biomarker can be free-floating within the balloon, or attached to an inner surface of the balloon or other inner structure by an adhesive or mechanical structure (net, fiber, cage, etc.).
  • the capsule will advantageously maintain its structural integrity until after it is placed in a sealed balloon (e.g., after the manufacturing process is completed, but not necessarily during storage of the fabricated balloon, prior to deployment of the balloon, or even during normal use of the balloon), with the balloon wall serving as containment for the biomarker incorporated within the uninflated balloon prior to deployment or the inflated balloon in normal use.
  • a sealed balloon e.g., after the manufacturing process is completed, but not necessarily during storage of the fabricated balloon, prior to deployment of the balloon, or even during normal use of the balloon
  • the balloon wall serving as containment for the biomarker incorporated within the uninflated balloon prior to deployment or the inflated balloon in normal use.
  • Different capsules containing different biomarkers can be employed in combination to achieve a desired effect.
  • a water soluble capsule to contain the biomarker
  • water is injected into the balloon during ejection from the catheter, with the water dissolving the capsule and solubilizes the biomarker therein, thereby making the biomarker (i.e., methylene blue dye) readily available for release in the event of balloon rupture or deflation permitting the entry of gastric fluid into the balloon.
  • the biomarker i.e., methylene blue dye
  • a quantity of the biomarker can be coated in a dissolvable polymer, a carbohydrate or other dissolvable or meltable material by techniques known in the pharmaceutical arts for encapsulation of active ingredients.
  • aliquots of the dry biomarker are pelletized using methods known in the art.
  • Such pellets of the biomarker can further be coated with dissolvable polymer or encapsulated in a gelatin or carbohydrate capsule.
  • the biomarker is mixed with a solvent, such as water, to form a thick paste or a solution.
  • a solvent such as water
  • a preselected amount of the biomarker paste or solution is dotted or printed onto the interior of the balloon, e.g., near the valve, such as via a micropipette or automated means (e.g., using screen printing or bubble jet techniques), and allowed to dry.
  • One or more dissolvable or water-soluble coatings can be applied over the one or more dots to facilitate the manufacturing process by reducing the possibility of contamination, or the dots can remain exposed.
  • the balloon assembly can proceed.
  • water released into the balloon from the ejection process dissolves the dried biomarker so as to make it available for indicating rupture and/or balloon deflation.
  • water is not deliberately injected into the balloon
  • exposure of the dried biomarker to gastric fluids upon failure of the balloon causes release of the biomarker.
  • Water vapor may also permeate the intact wall of the balloon during normal use, solubilizing the biomarker.
  • the biomarker does not permeate the intact wall of the balloon. Additional methods of aliquoting small amounts of the biomarker and preparing the aliquots for use during the balloon manufacturing process are envisioned.
  • the indicator component is in a gaseous form, it can be placed in the balloon during manufacturing by injection into the balloon, e.g., through a self sealing valve, or by assembling the balloon in an atmosphere comprising the gas.
  • the indicator component can be placed in the balloon by a physician or other individual administrating the balloon to a patient after manufacture, e.g., prior to, concurrent with, or after inflation in vivo, e.g., as a component of the initial fill gas, or as a component to the fill gas added separately.
  • Gaseous components typically can be employed so as to provide from 0.1 ppb (parts per billion on a weight basis) or less to 1000 ppb or more of the initial fill gas, e.g., 0.1-500 ppb, 0.1-400 ppb, 0.1-300 ppb, 0.1-200 ppb, 0.1-200 ppb, 0.1-100 ppb, 0.1-50 ppb, or 0.1-10 ppb.
  • Appropriate dyes that may be incorporated into the gastric balloon device to function as an indicator for balloon rupture are listed herein.
  • the characteristics of the dyes considered for selection included the following: acceptable toxicology profile, acceptable solubility, intensely absorbing (high color intensity), stable in the gastric environment, and stable during excretion so as to be visually identified by the patient or a caregiver.
  • the following dyes were identified as possessing the desired properties to make them suitable for use. These included, but were not limited to, fast green FCF (green emission), indigo carmine (blue emission), triamterene (blue emission), senna glycosides (red emission), and betanin (red emission).
  • the five above-referenced dyes are known to produce either a blue, blue- green, green or red urine color in humans. Methylene blue was also investigated due to its preexisting use as an indicator for gastric balloon leakage. Patients exposed to methylene blue are known to observe a blue-green discoloration of their urine as the compound is excreted. Two other compounds, Lumichrome and Lumiflavine, also produce blue-green urine but also exhibit poor solubility. Three additional compounds are known to alter the appearance of patient's urine to colors other than blue-green, including red and fluorescent yellow. Drugs known to have the side-effect of coloring patient's urine either blue-green or red were also identified as these might be a source of false positives for balloon leakages.
  • Methylene blue is a highly emissive blue dye that has found use based on its medicinal properties as well as its redox and emissive properties.
  • the chemical structure of methylene blue is provided below.
  • Urolene Blue is Urolene Blue and the typical dosage of methylene blue is 10 mg, but the dosage can vary. Methylene blue is also generally incorporated into sedatives and analgesics, including but not limited to the following (see Q.H. Meng, et. al. Ann. Lab. Med. 2013, 33, 457-458.): Propofol Prosed DS; Rinsapin.
  • Amounts of methylene blue providing a suitable effect in an intragastric balloon can be as low as 10 mg; however, higher amounts can also be employed, e.g., 15 mg, 20 mg, 25 mg, 30, mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 150 mg, 100 mg, 200 mg, or higher.
  • An amount of from about 15 mg to about 60 mg is typically employed, e.g., about 20-40 mg, e.g., about 30 mg. Similar amounts can also be employed for the other dyes identified herein.
  • the dye can be injected into the balloon in a liquid form, e.g., a pure liquid or a solution or suspension in a suitable liquid, e.g., water, ethanol, or any other physiological acceptable liquid, alone or in combination with other pharmaceutically acceptable excipients.
  • a suitable liquid e.g., water, ethanol, or any other physiological acceptable liquid, alone or in combination with other pharmaceutically acceptable excipients.
  • it can be provided in a solid form, e.g., a paste, a pellet, granules, powder, encapsulated form, or any other suitable form, either in a pure state or in combination with other pharmaceutically acceptable excipients.
  • BioEnterics Intragastric Balloon (BIB - Allergan Inc. as of 2012) is inflated by injecting saline solution mixed with methylene blue.
  • the methylene blue is incorporated as an indicator for balloon leakage. See “Endoluminal bariatric techniques.” Gastrointestinal Endoscopy 76, 1 (2012). It has been documented that the use of blue-green urine as an indicator for gastric balloon leakage is possible to yield a false positive. In the documented case, a patient detected the indicative green colored urine but did not have a leakage in their balloon. It was concluded that the urine discoloration originated from the use of propofol as a sedative. P. Bernante et al. Obesity Surgery 2003, 13, 951 -953.
  • Table 4 and Table 5 provide information regarding alternative dyes known to color urine.
  • Other drugs known to have the side-effect of turning urine blue green include, but are not limited to: amlodipine (Norvasc), sildenafil (Viagra), fosinopril (Monopril), Omeprazole (Prilosec), and pravastatin (Pravachol).
  • Daunorubicin http://www.drugs.com/sfx/daunorubicin-side-effects.html
  • phenazopyridine http://www.drugs.com/monograph/phenazopyridine-hydrochloride.html
  • rifampin http://www.drugs.com/monograph/rifampin.html
  • Asparagusic Acid (CAS # 2224-02-4, from asparagus) is one of the compounds known to give the characteristic odor to urine after the consumption of asparagus.
  • the odor is due to endocyclic disulfide motif of asparagusic acid (the ring-opened form does not cause the typical odor associated with eating asparagus).
  • a combination of two colors can create a unique diagnostic.
  • a combination of blue and red emission dyes (such as methylene blue and betalin) can create a unique diagnostic of purple urine if the pharmacokinetics of the dyes are complimentary and they excrete at similar times.
  • a group of items linked with the conjunction 'and' should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as 'and/or' unless expressly stated otherwise.
  • a group of items linked with the conjunction 'or' should not be read as requiring mutual exclusivity among that group, but rather should be read as 'and/or' unless expressly stated otherwise.
  • the articles 'a' and 'an' should be construed as referring to one or more than one (i.e., to at least one) of the grammatical objects of the article.
  • 'an element' means one element or more than one element.

Abstract

L'invention concerne des dispositifs et des méthodes de traitement de l'obésité. Plus particulièrement, l'invention concerne des appareils et des procédés pour empêcher des dispositifs intragastriques occupant le volume de passer dans le système digestif.
PCT/US2016/028143 2015-04-23 2016-04-18 Systèmes et procédés pour empêcher le passage de dispositifs intragastriques WO2016172054A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562151972P 2015-04-23 2015-04-23
US201562151967P 2015-04-23 2015-04-23
US62/151,967 2015-04-23
US62/151,972 2015-04-23

Publications (1)

Publication Number Publication Date
WO2016172054A1 true WO2016172054A1 (fr) 2016-10-27

Family

ID=57144169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/028143 WO2016172054A1 (fr) 2015-04-23 2016-04-18 Systèmes et procédés pour empêcher le passage de dispositifs intragastriques

Country Status (1)

Country Link
WO (1) WO2016172054A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
WO2022123555A1 (fr) * 2020-12-07 2022-06-16 Epitomee Medical Ltd. Dispositifs expansibles intragastriques
CN116602807A (zh) * 2023-05-22 2023-08-18 张勤生 一种胶囊式自产气胃减容减重气囊

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049677A1 (en) * 2001-11-09 2005-03-03 Farnan Robert C. Baloon catherter with non-deployable stent
US20050267596A1 (en) * 2004-05-03 2005-12-01 Fulfillium, Inc. A Delaware Corporation Devices and systems for gastric volume control
US20070100369A1 (en) * 2005-10-31 2007-05-03 Cragg Andrew H Intragastric space filler
US20080234718A1 (en) * 2003-10-23 2008-09-25 Pascal Paganon Ballasted Intragastric Balloon, Use Of An Absorbing Body And/Or Heavy Solid Bodies To Form A Ballast Inside Such A Balloon
US20100063530A1 (en) * 2005-06-01 2010-03-11 Nicolas Francois Michel Valencon Intra-gastric balloon with double-membrane valve and corresponding kit for setting same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049677A1 (en) * 2001-11-09 2005-03-03 Farnan Robert C. Baloon catherter with non-deployable stent
US20080234718A1 (en) * 2003-10-23 2008-09-25 Pascal Paganon Ballasted Intragastric Balloon, Use Of An Absorbing Body And/Or Heavy Solid Bodies To Form A Ballast Inside Such A Balloon
US20050267596A1 (en) * 2004-05-03 2005-12-01 Fulfillium, Inc. A Delaware Corporation Devices and systems for gastric volume control
US20100063530A1 (en) * 2005-06-01 2010-03-11 Nicolas Francois Michel Valencon Intra-gastric balloon with double-membrane valve and corresponding kit for setting same
US20070100369A1 (en) * 2005-10-31 2007-05-03 Cragg Andrew H Intragastric space filler

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
WO2022123555A1 (fr) * 2020-12-07 2022-06-16 Epitomee Medical Ltd. Dispositifs expansibles intragastriques
CN116602807A (zh) * 2023-05-22 2023-08-18 张勤生 一种胶囊式自产气胃减容减重气囊

Similar Documents

Publication Publication Date Title
US11730619B2 (en) Systems and methods for determining failure of intragastric devices
US11779482B2 (en) Intragastric device
US9173758B2 (en) Intragastric device
WO2016172054A1 (fr) Systèmes et procédés pour empêcher le passage de dispositifs intragastriques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16783659

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16783659

Country of ref document: EP

Kind code of ref document: A1